{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "!pip install -r requirements.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import json\n",
    "import requests\n",
    "import pandas as pd\n",
    "import pyodbc\n",
    "import openai\n",
    "from rich.console import Console\n",
    "from rich.panel import Panel\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "load_dotenv()\n",
    "console = Console()\n",
    "\n",
    "# Azure OpenAI configuration\n",
    "AZURE_OPENAI_API_KEY = os.getenv(\"AZURE_OPENAI_API_KEY\", \"your-azure-openai-api-key\")\n",
    "AZURE_OPENAI_API_VERSION = os.getenv(\"AZURE_OPENAI_API_VERSION\", \"2024-10-21\")\n",
    "AZURE_OPENAI_ENDPOINT = os.getenv(\"AZURE_OPENAI_ENDPOINT\", \"https://your-azure-openai-endpoint.openai.azure.com/\")\n",
    "AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME = os.getenv(\"AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME\", \"gpt-4o\")  # update as needed\n",
    "\n",
    "# Azure AI Search configuration\n",
    "AZURE_SEARCH_ENDPOINT = os.getenv(\"AZURE_SEARCH_SERVICE_ENDPOINT\", \"https://your-search-service.search.windows.net\")\n",
    "AZURE_SEARCH_KEY = os.getenv(\"AZURE_SEARCH_ADMIN_KEY\", \"your-azure-search-key\")\n",
    "SEARCH_INDEX_NAME = \"acc-guidelines-index\"\n",
    "\n",
    "\n",
    "# Bing Search credentials (optional)\n",
    "BING_SEARCH_API_KEY = os.getenv(\"BING_SEARCH_API_KEY\", \"<YOUR-BING-SEARCH-KEY>\")\n",
    "BING_SEARCH_ENDPOINT = \"https://api.bing.microsoft.com/v7.0/search\"\n",
    "\n",
    "# Import Azure libraries for search\n",
    "from azure.search.documents import SearchClient\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.search.documents.models import VectorizableTextQuery\n",
    "\n",
    "# Import Azure OpenAI client\n",
    "from openai import AzureOpenAI\n",
    "\n",
    "console = Console()\n",
    "\n",
    "# Azure SQL connection details (for patient data)\n",
    "server = os.getenv(\"AZURE_SQL_SERVER_NAME\")\n",
    "database = os.getenv(\"AZURE_SQL_DATABASE_NAME\")\n",
    "username = os.getenv(\"AZURE_SQL_USER_NAME\")\n",
    "password = os.getenv(\"AZURE_SQL_PASSWORD\")\n",
    "driver = '{ODBC Driver 17 for SQL Server}'\n",
    "\n",
    "# Create an Azure SQL connection string\n",
    "AZURE_SQL_CONNECTION_STRING = f\"DRIVER={driver};SERVER={server};DATABASE={database};UID={username};PWD={password}\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Initialize the Azure OpenAI client\n",
    "openai_client = AzureOpenAI(\n",
    "    api_key=AZURE_OPENAI_API_KEY,\n",
    "    api_version=AZURE_OPENAI_API_VERSION,\n",
    "    azure_endpoint=AZURE_OPENAI_ENDPOINT,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "from azure.search.documents import SearchClient\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.search.documents.models import VectorizableTextQuery\n",
    "\n",
    "def search_acc_guidelines(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Searches the Azure AI Search index 'acc-guidelines-index' \n",
    "    for relevant American College of Cardiology (ACC) guidelines.\n",
    "    \"\"\"\n",
    "    credential = AzureKeyCredential(AZURE_SEARCH_KEY)\n",
    "    client = SearchClient(\n",
    "        endpoint=AZURE_SEARCH_ENDPOINT,\n",
    "        index_name=SEARCH_INDEX_NAME,\n",
    "        credential=credential,\n",
    "    )\n",
    "    \n",
    "    results = client.search(\n",
    "        search_text=query,\n",
    "        vector_queries=[\n",
    "            VectorizableTextQuery(\n",
    "                text=query,\n",
    "                k_nearest_neighbors=10,   # Adjust as needed\n",
    "                fields=\"embedding\"   # Adjust based on your index schema\n",
    "            )\n",
    "        ],\n",
    "        query_type=\"semantic\",\n",
    "        semantic_configuration_name=\"default\",\n",
    "        search_fields=[\"chunk\"],\n",
    "        top=10,\n",
    "        include_total_count=True\n",
    "    )\n",
    "    \n",
    "    retrieved_texts = []\n",
    "    for result in results:\n",
    "        content_chunk = result.get(\"chunk\", \"\")\n",
    "        retrieved_texts.append(content_chunk)\n",
    "    \n",
    "    context_str = \"\\n\".join(retrieved_texts) if retrieved_texts else \"No relevant guidelines found.\"\n",
    "    \n",
    "    console.print(\n",
    "        Panel(\n",
    "            f\"Tool Invoked: ACC Guidelines Search\\nQuery: {query}\",\n",
    "            style=\"bold yellow\"\n",
    "        )\n",
    "    )\n",
    "    return context_str\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "def search_bing(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Searches the public web using the Bing Search API.\n",
    "    \"\"\"\n",
    "    headers = {\"Ocp-Apim-Subscription-Key\": BING_SEARCH_API_KEY}\n",
    "    params = {\"q\": query, \"textDecorations\": True, \"textFormat\": \"Raw\"}\n",
    "    response = requests.get(BING_SEARCH_ENDPOINT, headers=headers, params=params)\n",
    "    \n",
    "    if response.status_code == 200:\n",
    "        data = response.json()\n",
    "        if \"webPages\" in data and \"value\" in data[\"webPages\"]:\n",
    "            snippets = [item.get(\"snippet\", \"\") for item in data[\"webPages\"][\"value\"]]\n",
    "            result_text = \"\\n\".join(snippets)\n",
    "        else:\n",
    "            result_text = \"No Bing results found.\"\n",
    "    else:\n",
    "        result_text = f\"Bing search failed with status code {response.status_code}.\"\n",
    "    \n",
    "    console.print(\n",
    "        Panel(\n",
    "            f\"Tool Invoked: Bing Search\\nQuery: {query}\",\n",
    "            style=\"bold magenta\"\n",
    "        )\n",
    "    )\n",
    "    return result_text\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "import sqlalchemy\n",
    "\n",
    "def lookup_patient_data(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Queries the 'PatientMedicalData' table in Azure SQL and returns the results as a string.\n",
    "    'query' should be a valid SQL statement.\n",
    "    This version uses SQLAlchemy to create an engine, which is fully supported by pandas.read_sql.\n",
    "    \"\"\"\n",
    "    try:\n",
    "        # Construct the connection URI for SQLAlchemy\n",
    "        connection_uri = (\n",
    "            f\"mssql+pyodbc://{username}:{password}@{server}/{database}\"\n",
    "            \"?driver=ODBC+Driver+17+for+SQL+Server\"\n",
    "        )\n",
    "        engine = sqlalchemy.create_engine(connection_uri)\n",
    "        \n",
    "        # Use the engine in pandas.read_sql, which avoids the warning\n",
    "        df = pd.read_sql(query, engine)\n",
    "        if df.empty:\n",
    "            return \"No rows found.\"\n",
    "        return df.to_string(index=False)\n",
    "    except Exception as e:\n",
    "        return f\"Database error: {str(e)}\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "tools = [\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"search_acc_guidelines\",\n",
    "            \"description\": \"Query the ACC guidelines for official cardiology recommendations. Use keywords related to cardiology conditions, treatments, or guidelines.\",\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"Keywords or specific question related to cardiology guidelines.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    },\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"search_bing\",\n",
    "            \"description\": \"Perform a public web search for real-time or external information. For example, 'FDA new hyperlipidemia drugs', 'recent hypertension medication approvals'.\",\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"General query to retrieve public data.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    },\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"lookup_patient_data\",\n",
    "            \"description\": (\n",
    "                \"Query Azure SQL PatientMedicalData table. Schema: \"\n",
    "                \"PatientID: INT (PK, Identity), FirstName: VARCHAR(100), LastName: VARCHAR(100), \"\n",
    "                \"DateOfBirth: DATE, Gender: VARCHAR(20), ContactNumber: VARCHAR(100), EmailAddress: VARCHAR(100), \"\n",
    "                \"Address: VARCHAR(255), City: VARCHAR(100), PostalCode: VARCHAR(20), Country: VARCHAR(100), \"\n",
    "                \"MedicalCondition: VARCHAR(255), Medications: VARCHAR(255), Allergies: VARCHAR(255), BloodType: VARCHAR(10), \"\n",
    "                \"LastVisitDate: DATE, SmokingStatus: VARCHAR(50), AlcoholConsumption: VARCHAR(50), ExerciseFrequency: VARCHAR(50), \"\n",
    "                \"Occupation: VARCHAR(100), Height_cm: DECIMAL(5,2), Weight_kg: DECIMAL(5,2), BloodPressure: VARCHAR(20), \"\n",
    "                \"HeartRate_bpm: INT, Temperature_C: DECIMAL(3,1), Notes: VARCHAR(MAX). Use SQL to retrieve patient data.\"\n",
    "            ),\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"Valid SQL query for PatientMedicalData table to get patient information.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    }\n",
    "]\n",
    "\n",
    "# For convenience, map the tool name to the actual function\n",
    "tool_implementations = {\n",
    "    \"search_acc_guidelines\": search_acc_guidelines,\n",
    "    \"search_bing\": search_bing,\n",
    "    \"lookup_patient_data\": lookup_patient_data,\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [],
   "source": [
    "# ----------------------------\n",
    "# System Prompt for the Agent\n",
    "# ----------------------------\n",
    "SYSTEM_PROMPT = (\n",
    "    \"You are a cardiology-focused AI assistant with access to three tools:\\n\"\n",
    "    \"1) 'lookup_patient_data' for querying patient records from Azure SQL.\\n\"\n",
    "    \"2) 'search_acc_guidelines' for official ACC guidelines.\\n\"\n",
    "    \"3) 'search_bing' for real-time public information.\\n\\n\"\n",
    "    \"You can call these tools in any order, multiple times if needed, to gather all the context.\\n\"\n",
    "    \"Stop calling tools only when you have enough information to provide a final, cohesive answer.\\n\"\n",
    "    \"Then output your final answer to the user.\"\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "# ----------------------------\n",
    "# Agent Logic (Multi-Step) using new tools syntax\n",
    "# ----------------------------\n",
    "def run_multi_step_agent(user_query: str, max_steps: int = 10):\n",
    "    \"\"\"\n",
    "    A multi-step agent with enhanced debugging logs using the new tools syntax.\n",
    "    \"\"\"\n",
    "    messages = [\n",
    "        {\"role\": \"system\", \"content\": SYSTEM_PROMPT},\n",
    "        {\"role\": \"user\", \"content\": user_query}\n",
    "    ]\n",
    "\n",
    "    for step in range(max_steps):\n",
    "        console.print(Panel(f\"**Step {step+1}**: Starting step {step+1}\", title=\"Step Start\", style=\"bold cyan\"))\n",
    "        \n",
    "        response = openai_client.chat.completions.create(\n",
    "            model=AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME,\n",
    "            messages=messages,\n",
    "            tools=tools,\n",
    "            tool_choice=\"auto\",\n",
    "            max_tokens=8000,\n",
    "        )\n",
    "        response_message = response.choices[0].message\n",
    "        \n",
    "        console.print(Panel(f\"[DEBUG] Step {step+1}: Raw response_message: {response_message}\", title=\"Raw Response\", style=\"dim\"))\n",
    "        \n",
    "        # IMPORTANT: Append the assistant's message (which includes tool_calls) to the conversation.\n",
    "        messages.append(response_message)\n",
    "        \n",
    "        if response_message.tool_calls:\n",
    "            for tool_call in response_message.tool_calls:\n",
    "                function_name = tool_call.function.name\n",
    "                arguments_str = tool_call.function.arguments\n",
    "                \n",
    "                console.print(Panel(f\"[DEBUG] Step {step+1}: Tool called: {function_name}\", title=\"Tool Call Info\", style=\"bold magenta\"))\n",
    "                console.print(Panel(f\"[DEBUG] Step {step+1}: arguments_str: {arguments_str}\", title=\"Arguments String\", style=\"magenta\"))\n",
    "                \n",
    "                if arguments_str.strip() == \"\":\n",
    "                    function_args = {}\n",
    "                else:\n",
    "                    try:\n",
    "                        function_args = json.loads(arguments_str)\n",
    "                        console.print(Panel(f\"[DEBUG] Step {step+1}: function_args (JSON parsed): {function_args}\", title=\"Parsed Arguments\", style=\"green\"))\n",
    "                    except json.JSONDecodeError as e:\n",
    "                        function_args = {}\n",
    "                        console.print(\n",
    "                            Panel(\n",
    "                                \"Warning: Could not decode tool call arguments; defaulting to empty dict.\",\n",
    "                                title=\"JSONDecodeError\",\n",
    "                                style=\"bold red\"\n",
    "                            )\n",
    "                        )\n",
    "                        console.print(Panel(f\"[DEBUG] Step {step+1}: JSONDecodeError details: {e}\", title=\"JSONDecodeError Detail\", style=\"bold red\"))\n",
    "                        console.print(Panel(f\"[DEBUG] Step {step+1}: function_args (defaulted): {function_args}\", title=\"Defaulted Arguments\", style=\"red\"))\n",
    "                \n",
    "                # Ensure the 'query' key is present\n",
    "                if \"query\" not in function_args or not function_args[\"query\"]:\n",
    "                    function_args[\"query\"] = user_query\n",
    "                    console.print(Panel(f\"[DEBUG] Step {step+1}: 'query' key defaulted to user_query: {user_query}\", title=\"Defaulted Query Key\", style=\"yellow\"))\n",
    "                \n",
    "                console.print(\n",
    "                    Panel(\n",
    "                        f\"**Step {step+1}**: LLM calls tool [bold]{function_name}[/bold]\\n\\n\"\n",
    "                        f\"**Arguments**:\\n{json.dumps(function_args, indent=2)}\",\n",
    "                        title=\"Tool Call\",\n",
    "                        style=\"bold blue\"\n",
    "                    )\n",
    "                )\n",
    "                console.print(Panel(f\"[DEBUG] Step {step+1}: Calling tool implementation: {function_name} with args: {function_args}\", title=\"Tool Implementation Call\", style=\"bold magenta\"))\n",
    "                \n",
    "                tool_fn = tool_implementations.get(function_name)\n",
    "                if tool_fn is None:\n",
    "                    tool_output = f\"[Error] No implementation for tool '{function_name}'.\"\n",
    "                else:\n",
    "                    tool_output = tool_fn(**function_args)\n",
    "                console.print(Panel(f\"[DEBUG] Step {step+1}: Tool output: {tool_output}\", title=\"Tool Output\", style=\"italic blue\"))\n",
    "                \n",
    "                messages.append({\n",
    "                    \"tool_call_id\": tool_call.id,\n",
    "                    \"role\": \"tool\",\n",
    "                    \"name\": function_name,\n",
    "                    \"content\": tool_output,\n",
    "                })\n",
    "        else:\n",
    "            final_answer = response_message.content\n",
    "            console.print(\n",
    "                Panel(\n",
    "                    final_answer,\n",
    "                    title=\"Final Answer\",\n",
    "                    style=\"bold green\",\n",
    "                    border_style=\"yellow\"\n",
    "                )\n",
    "            )\n",
    "            return\n",
    "\n",
    "    console.print(\n",
    "        Panel(\n",
    "            \"Max steps reached without a final answer. Stopping.\",\n",
    "            title=\"Warning\",\n",
    "            style=\"bold red\"\n",
    "        )\n",
    "    )\n",
    "    return"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant',       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ audio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_csPEfaN6YbEmlFZ8NN9OKmNk',   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\":\"first-line therapy for hypertension in elderly patients\"}',              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ name='search_acc_guidelines'), type='function')])                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant', \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maudio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_csPEfaN6YbEmlFZ8NN9OKmNk', \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\":\"first-line therapy for hypertension in elderly patients\"}', \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mname='search_acc_guidelines'), type='function')])\u001b[0m\u001b[2m                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: search_acc_guidelines                                                              │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: search_acc_guidelines\u001b[0m\u001b[1;35m                                                             \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\":\"first-line therapy for hypertension in elderly patients\"}              │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\":\"first-line therapy for hypertension in elderly patients\"}\u001b[0m\u001b[35m             \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': 'first-line therapy for hypertension in elderly          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ patients'}                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': 'first-line therapy for hypertension in elderly \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpatients'}\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_acc_guidelines                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"first-line therapy for hypertension in elderly patients\"                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_acc_guidelines\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"first-line therapy for hypertension in elderly patients\"\u001b[0m\u001b[1;34m                                           \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: search_acc_guidelines with args: {'query': 'first-line therapy for │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ hypertension in elderly patients'}                                                                              │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: search_acc_guidelines with args: {'query': 'first-line therapy for\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mhypertension in elderly patients'}\u001b[0m\u001b[1;35m                                                                             \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Tool Invoked: ACC Guidelines Search                                                                             │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Query: first-line therapy for hypertension in elderly patients                                                  │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mTool Invoked: ACC Guidelines Search\u001b[0m\u001b[1;33m                                                                            \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mQuery: first-line therapy for hypertension in elderly patients\u001b[0m\u001b[1;33m                                                 \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output: # Whelton et al.                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2017 High Blood Pressure Clinical Practice Guideline                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # MAY 15, 2018: e127–248                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. The treatment of patients with hypertension without elevated risk has been systematically understudied       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ because lower-risk groups would require prolonged follow-up to have a sufficient number of clinical events to   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ provide useful information. Although there is clinical trial evidence that both drug and nondrug therapy will   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ interrupt the progressive course of hypertension (S8.1.5-6), there is no trial evidence that this treatment     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ decreases CVD morbidity and mortality. The clinical trial evidence is strongest for a target BP of 140/90 mm Hg │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ in this population. However, observational studies suggest that these individuals often have a high lifetime    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ risk and would benefit from BP control earlier in life (S8.1.5-19, S8.1.5-20).                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 8.1.6. Choice of Initial Medication                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation for Choice of Initial Medication                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ References that support the recommendation are summarized in Online Data Supplement 27 and Systematic Review    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Report.                                                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATION|                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|ASR|For initiation of antihypertensive drug therapy, first-line agents include thiazide diuretics, CCBs, and │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ACE inhibitors or ARBs. (S8.1.6-1, S8.1.6-2)|                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The overwhelming majority of persons with BP sufficiently elevated to warrant pharmacological therapy may be    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ best treated initially with 2 agents (see Section 8.1.6.1). When initiation of pharmacological therapy with a   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ single medication is appropriate, primary consideration should be given to comorbid conditions (e.g., HF, CKD)  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ for which specific classes of BP-lowering medication are indicated (see Section 9) (S8.1.6-1). In the largest   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ head-to-head comparison of first-step drug therapy for hypertension (S8.1.6-3), the thiazide-type diuretic      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ chlorthalidone was superior to the CCB amlodipine and the ACE inhibitor lisinopril in preventing HF, a          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ BP-related outcome of increasing importance in the growing population of older persons with hypertension        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S8.1.6-4—S8.1.6-7). Additionally, ACE inhibitors were less effective than thiazide diuretics and CCBs in       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ lowering BP and in prevention of stroke. For black patients, ACE inhibitors were also notably less effective    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ than CCBs in preventing HF (S8.1.6-8) and in the prevention of stroke (S8.1.6-9) (see Section 10.1). ARBs may   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ be better tolerated than ACE inhibitors in black patients, with less cough and angioedema, but according to the │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ limited available experience they offer no proven advantage over ACE inhibitors in preventing stroke or CVD in  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ this population, making thiazide diuretics (especially chlorthalidone) or CCBs the best initial choice for      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ single-drug therapy. For stroke, in the general population, beta blockers were less effective than CCBs (36%    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ lower risk) and thiazide diuretics (30% lower risk). CCBs have been shown to be as effective as diuretics for   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reducing all CVD events other than HF, and CCBs are a good alternative choice for initial therapy when thiazide │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ diuretics are not tolerated. Alpha blockers are not used as first-line therapy for hypertension because they    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ are less effective for prevention of CVD than other first-step agents, such as thiazide diuretics (S8.1.6-3,    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S8.1.6-10).                                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. The overall goal of treatment should be reduction in BP, in the context of underlying CVD risk. Five drug    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ classes have been shown, in high-quality RCTs, to prevent CVD as compared with placebo (diuretics, ACE          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ inhibitors, ARBs, CCBs, and beta blockers) (S8.1.6-11, S8.1.6-12). In head-to-head comparisons of first-step    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ therapy, different drug classes have been reported to provide somewhat divergent capacity to prevent specific   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ CVD events. Interpretation of meta-analyses comparing agents from different drug classes is challenging because │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ the relevant RCTs were conducted in different time periods, during which concurrent antihypertensive therapy    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ was less or more common, and the efficacy of agents from certain drug classes may have                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # JACC VOL. 79, NO. 17, 2022                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Heidenreich et al e329                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # MAY 3, 2022: e263 – e421                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2022 AHA/ACC/HFSA Heart Failure Guideline                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Extrapolated from those for treatment of patients with hypertension in general (26). However, the optimal blood │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ pressure goal and antihypertensive regimens are not known for patients with HFpEF. RAAS antagonists including   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ACEi, ARB, MRA, and possibly ARNi, could be first-line agents given experience with their use in HFpEF trials   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (8,10,16,20,27,28). Beta blockers may be used to treat hypertension in patients with a history of MI (27),      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ symptomatic CAD, or AF with rapid ventricular response. These effects need to be balanced with the potential    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ contribution of chronotropic incompetence to exercise intolerance in some patients (29).                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 1. EMPEROR-Preserved                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) showed a  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ significant benefit of the SGLT2i, empagliflozin, in symptomatic patients with HF with LVEF &gt;40% and elevated   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ natriuretic peptides (30). The 21% reduction in the primary composite endpoint of time to HF hospitalization or │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ cardiovascular death was driven mostly by a significant 29% reduction in time to HF hospitalization             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (nonsignificant lower cardiovascular death [HR, 0.91; 95% CI, 0.76-1.0]), with no benefit on all-cause          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mortality. Empagliflozin also resulted in a significant reduction in total HF hospitalizations, decrease in the │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ slope of the eGFR decline, and a modest improvement in QOL at 52 weeks. Of note, the benefit was similar        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ irrespective of the presence or absence of diabetes at baseline. Although the benefit in the primary endpoint   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ did not have a significant interaction by LVEF subgroups (&lt;50%, 50%–&lt;60%, and &gt;60%) (30), in a subgroup         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ analysis by EF, there was a signal for lower benefit on the primary composite endpoint, first and recurrent HF  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hospitalizations at higher LVEFs &gt;62.5% (31).                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2. Atrial Fibrillation Management                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Large, randomized clinical trial data are unavailable to specifically guide therapy in patients with HFpEF and  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ AF. Currently, the comprehensive care of AF can be extrapolated from the clinical practice guidelines for AF,   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ with individualization of strategies for rate or rhythm control in patients with HFpEF (see also Section 10.2,  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ “Management of Atrial Fibrillation (AF) in HF,” for HF specific recommendations for AF). Although beta blockers │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and nondihydropyridine calcium channel blockers are often considered as first-line agents for heart rate        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ control in patients with HFpEF, a recent smaller open-label trial, RATE-AF in elderly patients with AF and      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ symptoms of HF (most with preserved LVEF), compared the use of the beta blocker, bisoprolol, to digoxin (32).   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ At 6 months, the primary endpoint of QOL was similar between the 2 groups. However, several secondary QOL       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ endpoints, functional capacity, and reduction in NT-proBNP favored digoxin at 12 months. There was a similar    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ heart rate reduction in both groups. Of note, more adverse events such as higher rates of dizziness, lethargy,  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and hypotension occurred with beta blockers than digoxin. The comprehensive care of AF is beyond the scope of   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ these guidelines. AF-specific care recommendations can be found in separate ACC/AHA clinical practice           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ guidelines (33,34).                                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 3. MRAs and Diastolic Function                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ MRAs improve diastolic function in patients with HFpEF (35). The TOPCAT trial investigated the effects of       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ spironolactone in patients with HFpEF. The small reduction (HR, 0.89) in the composite of death, aborted        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ cardiac death, and HF hospitalization was not statistically significant, although HF hospitalization was        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduced (HR, 0.83); adverse effects of hyperkalemia and increasing creatinine levels were more common in the    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ treatment group (5). A post hoc analysis (6) showed efficacy in the Americas (HR 0.83) but not in               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Russia-Georgia (HR 1.10). A sample of the Russia-Georgia population in the active treatment arm had             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ non-detectable levels of a spironolactone metabolite. Post hoc analyses have limitations, but they suggest a    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ possibility of benefit in appropriately selected patients with symptomatic HFpEF                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Whelton et al.                                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2017 High Blood Pressure Clinical Practice Guideline                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # MAY 15, 2018: e127–248                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # TABLE 19                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Intravenous Antihypertensive Drugs for Treatment of Hypertensive Emergencies                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Class|Drug(s)|Usual Dose Range|Comments|                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|---|                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |CCB—dihydropyridines|Nicardipine|Initial 5 mg/h, increasing every 5 min by 2.5 mg/h to maximum 15              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mg/h.|Contraindicated in advanced aortic stenosis; no dose adjustment needed for elderly.|                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ | |Clevidipine|Initial 1–2 mg/h, doubling every 90 s until BP approaches target, then increasing by less than   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ double every 5–10 min; maximum dose 32 mg/h; maximum duration 72 h.|Contraindicated in patients with soybean,   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ soy product, egg, and egg product allergy and in patients with defective lipid metabolism (e.g., pathological   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hyperlipidemia, lipoid nephrosis or acute pancreatitis). Use low-end dose range for elderly patients.|          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Vasodilators—Nitric-oxide dependent|Sodium nitroprusside|Initial 0.3–0.5 mcg/kg/min; increase in increments of │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 0.5 mcg/kg/min to achieve BP target; maximum dose 10 mcg/kg/min; duration of treatment as short as possible.    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ For infusion rates ≥4–10 mcg/kg/min or duration &gt;30 min, thiosulfate can be coadministered to prevent cyanide   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ toxicity.|Intra-arterial BP monitoring recommended to prevent “overshoot.” Lower dosing adjustment required for │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ elderly. Tachyphylaxis common with extended use. Cyanide toxicity with prolonged use can result in irreversible │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ neurological changes and cardiac arrest.|                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ | |Nitroglycerin|Initial 5 mcg/min; increase in increments of 5 mcg/min every 3–5 min to a maximum of 20        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mcg/min.|Use only in patients with acute coronary syndrome and/or acute pulmonary edema. Do not use in          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ volume-depleted patients.|                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Vasodilators—direct|Hydralazine|Initial 10 mg via slow IV infusion (maximum initial dose 20 mg); repeat every  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4–6 h as needed.|BP begins to decrease within 10–30 min, and the fall lasts 2–4 h. Unpredictability of response │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and prolonged duration of action do not make hydralazine a desirable first-line agent for acute treatment in    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ most patients.|                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Adrenergic blockers—beta1 receptor selective antagonist|Esmolol|Loading dose 500–1000 mcg/kg/min over 1 min    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ followed by a 50-mcg/kg/min infusion. For additional dosing, the bolus dose is repeated and the infusion        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ increased in 50-mcg/kg/min increments as needed to a maximum of 200 mcg/kg/min.|Contraindicated in patients     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ with concurrent beta-blocker therapy, bradycardia, or decompensated HF. Monitor for bradycardia. May worsen HF. │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Higher doses may block beta2 receptors and impact lung function in reactive airway disease.|                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Adrenergic blockers—combined alpha1 and nonselective beta receptor antagonist|Labetalol|Initial 0.3–1.0-mg/kg  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ dose (maximum 20 mg) slow IV injection every 10 min or 0.4–1.0-mg/kg/h IV infusion up to 3 mg/kg/h. Adjust rate │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ up to total cumulative dose of 300 mg. This dose can be repeated every 4–6 h.|Contraindicated in reactive       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ airways disease or chronic obstructive pulmonary disease. Especially useful in hyperadrenergic syndromes. May   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ worsen HF and should not be given in patients with second- or third-degree heart block or bradycardia.|         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Adrenergic blockers—nonselective alpha receptor antagonist|Phentolamine|IV bolus dose 5 mg. Additional bolus   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ doses every 10 min as needed to lower BP to target.|Used in hypertensive emergencies induced by catecholamine   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ excess (pheochromocytoma, interactions between monoamine oxidase inhibitors and other drugs or food, cocaine    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ toxicity, amphetamine overdose, or clonidine withdrawal).|                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Dopamine-receptor1 selective agonist|Fenoldopam|Initial 0.1–0.3                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ \"first-line\" medication choices|                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |ACE inhibitor intolerant| |                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Yes|ARB *|                                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |No|ACF inhibitor|                                                                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Colors correspond to Class of Recommendation in Table 1. *CKD stage 3 or higher or stage 1 or 2 with            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ albuminuria ≥300 mg/d or ≥300 mg/g creatinine. ACE indicates angiotensin-converting enzyme; ARB, angiotensin    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ receptor blocker; BP blood pressure; and CKD, chronic kidney disease.                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ An ACE inhibitor (or an ARB, in case of ACE inhibitor intolerance) is a preferred drug for treatment of         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypertension if albuminuria (≥300 mg/day or ≥300 mg/g creatinine by first morning void) is present, although    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ the evidence is mixed (S9.3-10,S9.3-11) (Figure 6). In the course of reducing intraglomerular pressure and      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ thereby reducing albuminuria, serum creatinine may increase up to 30% because of concurrent reduction in GFR    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S9.3-32). Further GFR decline should be investigated and may be related to other factors, including volume     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ contraction, use of nephrotoxic agents, or renovascular disease (S9.3-33). The combination of an ACE inhibitor  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and an ARB should be avoided because of reported harms demonstrated in several large cardiology trials          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S9.3-34,S9.3-35) and in 1 diabetic nephropathy trial (S9.3-36). Because of the greater risk of hyperkalemia    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and hypotension and lack of...                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Whelton et al. e173                                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # M A Y 1 5 , 2 0 1 8 : e 1 2 7 – 2 4 8                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2017 High Blood Pressure Clinical Practice Guideline                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Compelling indications for treatment of SIHD, these drugs are recommended as a first-line therapy in the        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ treatment of hypertension when it occurs in patients with SIHD. GDMT beta blockers for SIHD that are also       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ effective in lowering BP include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol,    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ propranolol, and timolol. Atenolol is not as effective as other antihypertensive drugs in the treatment of      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypertension (S9.1-23).                                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Dihydropyridine CCBs are effective antianginal drugs that can lower BP and relieve angina pectoris when added   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ to beta blockers in patients in whom hypertension is present and angina pectoris persists despite beta-blocker  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ therapy (S9.1-8,S9.1-17,S9.1-19—S9.1-22,S9.1-24,S9.1-25). GDMT beta blockers for SIHD that are also effective   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ in lowering BP include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, propranolol, │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and timolol.                                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ In randomized long-term trials, use of beta blockers after MI reduced all-cause mortality by 23% (S9.1-13).     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Given the established efficacy of beta blockers for treating hypertension and SIHD, their use for treatment     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ continuing beyond 3 years after MI is reasonable (S9.1-6,S9.1-25).                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ GDMT beta blockers and CCBs are effective antihypertensive and antianginal agents. CCBs include dihydropyridine │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and nondihydropyridine agents. CCBs can be used separately or together with beta blockers beginning 3 years     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ after MI in patients with CAD who have both hypertension and angina.                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 9.2. Heart Failure                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation for Prevention of HF in Adults With Hypertension                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ References that support the recommendation are summarized in Online Data Supplement 33.                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATION|                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |SBP: B-R|I|In adults at increased risk of HF, the optimal BP in those with hypertension should be less than    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 130/80 mm Hg (S9.2-1—S9.2-3).|                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |DBP: C-EO| | |                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Antecedent hypertension is present in 75% of patients with chronic HF (S9.2-4). In the Cardiovascular Health    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Study (S9.2-5) and the Health, Aging and Body Composition Study (S9.2-6), 11.2% of 4408 persons (53.1% women,   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ with a mean age of 72.8 years, living in the community, and not receiving antihypertensive drugs at baseline)   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ developed HF over 10 years (S9.2-7). Compared with those with an average SBP &lt;120 mm Hg, the adjusted incidence │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of HF was increased 1.6, 2.2, and 2.6 times in those with average SBPs between 120 and 139 mm Hg, between 140   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and 159 mm Hg, and ≥160 mm Hg, respectively (S9.2-7).                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ No RCTs are available that compare one BP-lowering agent to another for the management of patients with HF. The │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ following recommendations for treatment of hypertension in HF are based on use of drugs that lower BP and also  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ have compelling indications for management of HF (with HFrEF or HFpEF) as recommended in current ACC/AHA        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ guidelines (S9.2-4,S9.2-8).                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. In adults with hypertension (SBP ≥130 mm Hg or DBP ≥80 mm Hg) and a high risk of CVD, a strong               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ recommendation for BP lowering (&lt;130 mm Hg) is higher than that used in SPRINT.                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ or diltiazem are recommended, with the choice of agents according to patient preferences and comorbid           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ conditions.|                                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |2a|C-LD|In patients with HCM and subclinical AF detected by internal or external device or monitor, of &gt;5      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ minutes’ duration but &lt;24 hours’ duration for a given episode, anticoagulation with DOACs as first-line option  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and vitamin K antagonists as second-line option can be beneficial, taking into consideration duration of AF     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ episodes, total AF burden, underlying risk factors, and bleeding risk.|                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |2a|B-NR|In patients with HCM and poorly tolerated AF, a rhythm-control strategy with cardioversion or          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ antiarrhythmic drugs can be beneficial with the choice of an agent according to AF symptom severity, patient    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ preferences, and comorbid conditions.|                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |2a|B-NR|In patients with HCM and symptomatic AF, as part of an AF rhythm-control strategy, catheter ablation   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ for AF can be effective when drug therapy is ineffective, contraindicated, or not the patient’s preference.|    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |2a|B-NR|In patients with HCM and AF who require surgical myectomy, concomitant surgical AF ablation procedure  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ can be beneficial for AF rhythm control.|                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 71, N O . 1 9, 2 0 1 8                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Whelton et al. e169                                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # M A Y 1 5, 2 0 1 8 : e 1 2 7 – 2 4 8                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2017 High Blood Pressure Clinical Practice Guideline                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ significantly better than CCBs for prevention of HF. There were some other nonsignificant differences between   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ diuretics, ACE inhibitors, ARBs, and CCBs, but the general pattern was for similarity in effect. As indicated   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ in Section 8.1.6.1, most adults with hypertension require &gt;1 drug to control their BP. As recommended in        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Section 10.1, for black adults with hypertension (without HF or CKD), initial antihypertensive treatment should │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ include a thiazide diuretic or CCB.                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 8.1.6.1. Choice of Initial Monotherapy Versus Initial Combination Drug Therapy                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|C-EO|Initiation of antihypertensive drug therapy with 2 first-line agents of different classes, either as    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ separate agents or in a fixed-dose combination, is recommended in adults with stage 2 hypertension and an       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ average BP more than 20/10 mm Hg above their BP target.|                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|C-EO|Initiation of antihypertensive drug therapy with a single antihypertensive drug is reasonable in      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ adults with stage 1 hypertension and BP goal &lt;130/80 mm Hg with dosage titration and sequential addition of     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ other agents to achieve the BP target.|                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ *Fixed-dose combination antihypertensive medications are listed in Online Data Supplement D.                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Systematic review of the evidence comparing the initiation of antihypertensive treatment with monotherapy and   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ sequential (stepped-care) titration of additional agents versus initiation of treatment with combination        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ therapy (including fixed-dose combinations) did not identify any RCTs meeting the systematic review questions   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ posed in the PICOTS format (P¼population, I¼intervention, C¼comparator, O¼outcome, T¼timing, S¼setting).        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ However, in both ACCORD and SPRINT, 2-drug therapy was recommended for most participants in the intensive- but  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ not standard-therapy groups.                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Because most patients with hypertension require multiple agents for control of their BP and those with       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ higher BPs are at greater risk, more rapid titration of antihypertensive medications began to be recommended in │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ patients with BP &gt;20/10 mm Hg above their target, beginning with the JNC 7 report (S8.1.6.1-1). In these        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ patients, initiation of antihypertensive therapy with 2 agents is recommended. Evidence favoring this approach  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ comes mostly from studies using fixed-dose combination products showing greater BP lowering with fixed-dose     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ combination agents than with single agents, as well as better adherence to therapy (S8.1.6.1-2,S8.1.6.1-3). The │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ safety and efficacy of this strategy have been demonstrated in adults to reduce BPs to &lt;140/90 mm Hg though not │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ compared with other strategies (S8.1.6.1-4—S8.1.6.1-6). In general, this approach is reasonable in older        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ adults, those at high CVD risk, or those who have a history of hypotension or drug-associated side effects.     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ However, caution is advised in initiating antihypertensive pharmacotherapy with 2 drugs in older patients       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ because hypotension or orthostatic hypotension may develop in some patients; BP should be carefully monitored.  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. The stepped-care approach defined by the initiation of antihypertensive drug therapy with a single agent     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ followed by the sequential titration of the dose and addition of other agents has been the recommended          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ treatment strategy since the first report of the National High Blood Pressure Education Program (S8.1.6.1-7).   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ This approach is also reasonable in older adults or those at risk or who have a history of hypotension or       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ drug-associated side effects. This strategy has been used successfully in nearly all hypertension treatment     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ trials but has not been formally tested against other antihypertensive drug treatment strategies for            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ effectiveness in achieving BP control or in preventing adverse outcomes.                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 8.2. Achieving BP Control in Individual Patients                                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Recommendations for lifestyle modifications and drug selection are specified in                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ therapy should be assessed within 3 to 6 months.                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. Nonpharmacological therapy can help reduce BP in patients with stage 1 hypertension with an estimated        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 10-year ASCVD risk of ≥10% and should be used in addition to pharmacological therapy as first-line therapy in   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ such patients (see Section 6.2).                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 3. Prompt evaluation and treatment of patients with stage 2 hypertension with a combination of drug and         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ non-pharmacological therapy are important because of the elevated risk of CVD events in this subgroup,          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ especially those with multiple ASCVD risk factors or target organ damage (S8.1.3-1,S8.1.3-2).                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4. Prompt management of very high BP is important to reduce the risk of target organ damage (see Section 11.2). │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The rapidity of the treatment needed is dependent on the patient’s clinical presentation (presence of new or    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ worsening target organ damage) and presence or absence of CVD complications, but treatment should be initiated  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ within at least 1 week.                                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Whelton et al.                                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2017 High Blood Pressure Clinical Practice Guideline                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # M A Y  1 5 , 2 0 1 8 : e 1 2 7 – 2 4 8                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 9.1. Stable Ischemic Heart Disease                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendations for Treatment of Hypertension in Patients With Stable Ischemic Heart Disease (SIHD)           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ References that support recommendations are summarized in Online Data Supplements 30-32.                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |SBP: B-R|I|1. In adults with SIHD and hypertension, a BP target of less than 130/80 mm Hg is recommended       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S9.1-1—S9.1-5).|                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |DBP: C-EO| | |                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |SBP: B-R|I|2. Adults with SIHD and hypertension (BP ≥130/80 mm Hg) should be treated with medications (e.g.,   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ GDMT beta blockers, ACE inhibitors, or ARBs) for compelling indications (e.g., previous MI, stable angina) as   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ first-line therapy, with the addition of other drugs (e.g., dihydropyridine CCBs, thiazide diuretics, and/or    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mineralocorticoid receptor antagonists) as needed to further control hypertension (S9.1-6) (S9.1-7—S9.1-10).|   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ | |B-NR|3. In adults with SIHD with angina and persistent uncontrolled hypertension, the addition of            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ dihydropyridine CCBs to GDMT (S9.1-6) beta blockers is recommended (S9.1-8,S9.1-11,S9.1-12).|                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ | |IIa|4. In adults who have had a MI or acute coronary syndrome, it is reasonable to continue GDMT (S9.1-6)    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ beta blockers beyond 3 years as long-term therapy for hypertension (S9.1-13,S9.1-14).|                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ | |IIb|5. Beta blockers and/or CCBs might be considered to control hypertension in patients with CAD (without   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ HFrEF) who had an MI more than 3 years ago and have angina.|                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Hypertension is a major risk factor for ischemic heart disease. Numerous RCTs have demonstrated the benefits of │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ antihypertensive drug therapy in reducing the risk of ischemic heart disease. The following recommendations     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ apply only to management of hypertension in patients with SIHD without HF. See Section 9.2 for recommendations  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ for the treatment of patients with SIHD and HF.                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Figure 5 is an algorithm on management of hypertension in patients with SIHD.                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. In patients with increased cardiovascular risk, reduction of SBP to &lt;130/80 mm Hg has been shown to reduce   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ CVD complications by 25% and all-cause mortality by 27% (S9.1-1).                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. After 5 years of randomized therapy in high-CVD-risk patients, ramipril produced a 22% reduction in MI,      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ stroke, or CVD compared with placebo (S9.1-10). No added benefit on CVD outcomes was seen when compared with    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ CCBs and diuretics (S9.1-15,S9.1-16). After 4.2 years of randomized therapy in patients with SIHD, perindopril  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduced CVD death, MI, or cardiac arrest by 20% compared with placebo (S9.1-7). Beta blockers are effective     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ drugs for preventing angina pectoris, improving exercise time until the onset of angina pectoris, reducing      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ exercise-induced ischemic ST-segment depression, and preventing coronary events (S9.1-8,S9.1-17—S9.1-22).       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # F I G U R E 5 Management of Hypertension in Patients With SIHD                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Hypertension With SIHD                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Reduce BP to &lt;130/80 mm Hg with GDMT beta blockers, ACE inhibitor, or ARBs (Class I)                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ BP goal not met                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Angina pectoris                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ No                                                                                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Add dihydropyridine CCBs if needed (Class I)                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Add dihydropyridine CCBs; thiazide-type                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Whelton et al. e163                                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # M A Y 1 5 , 2 0 1 8 : e 1 2 7 – 2 4 8                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2017 High Blood Pressure Clinical Practice Guideline                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ risk of CVD (S8.1.2-12,S8.1.2-13). Indirect support is also provided by evidence from trials using BP-lowering  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ medications to reduce the risk of developing higher levels of BP (S8.1.2-59—S8.1.2-61) and, in one case, to     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ achieve a reduction in LV mass (S8.1.2-62). In the HOPE-3 (Heart Outcomes Prevention Evaluation-3) BP Trial,    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ there was no evidence of short-term benefit during treatment of adults (average age 66 years) with a relatively │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ low risk of CVD (3.8% CVD event rate during 5.6 years of follow-up). However, subgroup analysis suggested       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ benefit in those with an average SBP approximately &gt;140 mm Hg (and a CVD risk of 6.5% during the 5.6 years of   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ follow-up) (S8.1.2-63). We acknowledge the importance of excluding white coat hypertension before initiating    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ pharmacological therapy in hypertensive patients with low ASCVD risk. This may be accomplished (as described in │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Section 4) by HBPM or ABPM as appropriate.                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 8.1.3. Follow-Up After Initial BP Evaluation                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendations for Follow-Up After Initial BP Evaluation                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ References that support recommendations are summarized in Online Data Supplement 24.                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-R|Adults with an elevated BP or stage 1 hypertension who have an estimated 10-year ASCVD risk less than    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 10% should be managed with nonpharmacological therapy and have a repeat BP evaluation within 3 to 6 months      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S8.1.3-1,S8.1.3-2).|                                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-R|Adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of 10% or higher should be     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ managed initially with a combination of nonpharmacological and antihypertensive drug therapy and have a repeat  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ BP evaluation in 1 month (S8.1.3-1,S8.1.3-2).|                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-R|Adults with stage 2 hypertension should be evaluated by or referred to a primary care provider within 1  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ month of the initial diagnosis, have a combination of nonpharmacological and antihypertensive drug therapy      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (with 2 agents of different classes) initiated, and have a repeat BP evaluation in 1 month                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S8.1.3-1,S8.1.3-2).|                                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-R|For adults with a very high average BP (e.g., SBP ≥180 mm Hg or DBP ≥110 mm Hg), evaluation followed by  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ prompt antihypertensive drug treatment is recommended (S8.1.3-1,S8.1.3-2).|                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|C-EO|For adults with a normal BP, repeat evaluation every year is reasonable.|                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ An important component of BP management in hypertensive patients is follow-up. Different periods of time for    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ follow-up are recommended depending on the stage of hypertension, the presence or absence of target organ       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ damage, treatment with antihypertensive medications, and the level of BP control. Recommendations for follow-up │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ are summarized in Figure 4.                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Nonpharmacological therapy (see Section 6.2) is the preferred therapy for adults with elevated BP and an     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ appropriate first-line therapy for adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ &lt;10%. Adherence to and impact of non-pharmacological therapy should be assessed within 3 to 6 months.           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. Nonpharmacological therapy can help reduce BP in patients with stage 1 hypertension with an estimated        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 10-year ASCVD risk of ≥10% and should be used in addition to pharmacological therapy as first-line therapy in   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ such patients (see Section 6.2).                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 3. Prompt evaluation and treatment of patients with stage 2 hypertension with a combination of drug and         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ non-pharmacological therapy are important because of the elevated risk of CVD                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output: # Whelton et al.\u001b[0m\u001b[3;34m                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2017 High Blood Pressure Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# MAY 15, 2018: e127–248\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. The treatment of patients with hypertension without elevated risk has been systematically understudied \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbecause lower-risk groups would require prolonged follow-up to have a sufficient number of clinical events to \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mprovide useful information. Although there is clinical trial evidence that both drug and nondrug therapy will \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34minterrupt the progressive course of hypertension (S8.1.5-6), there is no trial evidence that this treatment \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdecreases CVD morbidity and mortality. The clinical trial evidence is strongest for a target BP of 140/90 mm Hg\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34min this population. However, observational studies suggest that these individuals often have a high lifetime \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mrisk and would benefit from BP control earlier in life (S8.1.5-19, S8.1.5-20).\u001b[0m\u001b[3;34m                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 8.1.6. Choice of Initial Medication\u001b[0m\u001b[3;34m                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation for Choice of Initial Medication\u001b[0m\u001b[3;34m                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferences that support the recommendation are summarized in Online Data Supplement 27 and Systematic Review \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReport.\u001b[0m\u001b[3;34m                                                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATION|\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|ASR|For initiation of antihypertensive drug therapy, first-line agents include thiazide diuretics, CCBs, and\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mACE inhibitors or ARBs. (S8.1.6-1, S8.1.6-2)|\u001b[0m\u001b[3;34m                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Synopsis\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe overwhelming majority of persons with BP sufficiently elevated to warrant pharmacological therapy may be \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbest treated initially with 2 agents (see Section 8.1.6.1). When initiation of pharmacological therapy with a \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msingle medication is appropriate, primary consideration should be given to comorbid conditions (e.g., HF, CKD) \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfor which specific classes of BP-lowering medication are indicated (see Section 9) (S8.1.6-1). In the largest \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhead-to-head comparison of first-step drug therapy for hypertension (S8.1.6-3), the thiazide-type diuretic \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mchlorthalidone was superior to the CCB amlodipine and the ACE inhibitor lisinopril in preventing HF, a \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mBP-related outcome of increasing importance in the growing population of older persons with hypertension \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S8.1.6-4—S8.1.6-7). Additionally, ACE inhibitors were less effective than thiazide diuretics and CCBs in \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlowering BP and in prevention of stroke. For black patients, ACE inhibitors were also notably less effective \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthan CCBs in preventing HF (S8.1.6-8) and in the prevention of stroke (S8.1.6-9) (see Section 10.1). ARBs may \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbe better tolerated than ACE inhibitors in black patients, with less cough and angioedema, but according to the\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlimited available experience they offer no proven advantage over ACE inhibitors in preventing stroke or CVD in \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthis population, making thiazide diuretics (especially chlorthalidone) or CCBs the best initial choice for \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msingle-drug therapy. For stroke, in the general population, beta blockers were less effective than CCBs (36% \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlower risk) and thiazide diuretics (30% lower risk). CCBs have been shown to be as effective as diuretics for \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreducing all CVD events other than HF, and CCBs are a good alternative choice for initial therapy when thiazide\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdiuretics are not tolerated. Alpha blockers are not used as first-line therapy for hypertension because they \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mare less effective for prevention of CVD than other first-step agents, such as thiazide diuretics (S8.1.6-3, \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS8.1.6-10).\u001b[0m\u001b[3;34m                                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation-Specific Supportive Text\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. The overall goal of treatment should be reduction in BP, in the context of underlying CVD risk. Five drug \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mclasses have been shown, in high-quality RCTs, to prevent CVD as compared with placebo (diuretics, ACE \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34minhibitors, ARBs, CCBs, and beta blockers) (S8.1.6-11, S8.1.6-12). In head-to-head comparisons of first-step \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtherapy, different drug classes have been reported to provide somewhat divergent capacity to prevent specific \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCVD events. Interpretation of meta-analyses comparing agents from different drug classes is challenging because\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthe relevant RCTs were conducted in different time periods, during which concurrent antihypertensive therapy \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwas less or more common, and the efficacy of agents from certain drug classes may have\u001b[0m\u001b[3;34m                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# JACC VOL. 79, NO. 17, 2022\u001b[0m\u001b[3;34m                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Heidenreich et al e329\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# MAY 3, 2022: e263 – e421\u001b[0m\u001b[3;34m                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2022 AHA/ACC/HFSA Heart Failure Guideline\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mExtrapolated from those for treatment of patients with hypertension in general (26). However, the optimal blood\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpressure goal and antihypertensive regimens are not known for patients with HFpEF. RAAS antagonists including \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mACEi, ARB, MRA, and possibly ARNi, could be first-line agents given experience with their use in HFpEF trials \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(8,10,16,20,27,28). Beta blockers may be used to treat hypertension in patients with a history of MI (27), \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msymptomatic CAD, or AF with rapid ventricular response. These effects need to be balanced with the potential \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcontribution of chronotropic incompetence to exercise intolerance in some patients (29).\u001b[0m\u001b[3;34m                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 1. EMPEROR-Preserved\u001b[0m\u001b[3;34m                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) showed a \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msignificant benefit of the SGLT2i, empagliflozin, in symptomatic patients with HF with LVEF >40% and elevated \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mnatriuretic peptides (30). The 21% reduction in the primary composite endpoint of time to HF hospitalization or\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcardiovascular death was driven mostly by a significant 29% reduction in time to HF hospitalization \u001b[0m\u001b[3;34m           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(nonsignificant lower cardiovascular death [HR, 0.91; 95% CI, 0.76-1.0]), with no benefit on all-cause \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmortality. Empagliflozin also resulted in a significant reduction in total HF hospitalizations, decrease in the\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mslope of the eGFR decline, and a modest improvement in QOL at 52 weeks. Of note, the benefit was similar \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mirrespective of the presence or absence of diabetes at baseline. Although the benefit in the primary endpoint \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdid not have a significant interaction by LVEF subgroups (<50%, 50%–<60%, and >60%) (30), in a subgroup \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34manalysis by EF, there was a signal for lower benefit on the primary composite endpoint, first and recurrent HF \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhospitalizations at higher LVEFs >62.5% (31).\u001b[0m\u001b[3;34m                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2. Atrial Fibrillation Management\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLarge, randomized clinical trial data are unavailable to specifically guide therapy in patients with HFpEF and \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAF. Currently, the comprehensive care of AF can be extrapolated from the clinical practice guidelines for AF, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwith individualization of strategies for rate or rhythm control in patients with HFpEF (see also Section 10.2, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m“Management of Atrial Fibrillation (AF) in HF,” for HF specific recommendations for AF). Although beta blockers\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand nondihydropyridine calcium channel blockers are often considered as first-line agents for heart rate \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcontrol in patients with HFpEF, a recent smaller open-label trial, RATE-AF in elderly patients with AF and \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msymptoms of HF (most with preserved LVEF), compared the use of the beta blocker, bisoprolol, to digoxin (32). \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAt 6 months, the primary endpoint of QOL was similar between the 2 groups. However, several secondary QOL \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mendpoints, functional capacity, and reduction in NT-proBNP favored digoxin at 12 months. There was a similar \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mheart rate reduction in both groups. Of note, more adverse events such as higher rates of dizziness, lethargy, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand hypotension occurred with beta blockers than digoxin. The comprehensive care of AF is beyond the scope of \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthese guidelines. AF-specific care recommendations can be found in separate ACC/AHA clinical practice \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mguidelines (33,34).\u001b[0m\u001b[3;34m                                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 3. MRAs and Diastolic Function\u001b[0m\u001b[3;34m                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mMRAs improve diastolic function in patients with HFpEF (35). The TOPCAT trial investigated the effects of \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mspironolactone in patients with HFpEF. The small reduction (HR, 0.89) in the composite of death, aborted \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcardiac death, and HF hospitalization was not statistically significant, although HF hospitalization was \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduced (HR, 0.83); adverse effects of hyperkalemia and increasing creatinine levels were more common in the \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtreatment group (5). A post hoc analysis (6) showed efficacy in the Americas (HR 0.83) but not in \u001b[0m\u001b[3;34m             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mRussia-Georgia (HR 1.10). A sample of the Russia-Georgia population in the active treatment arm had \u001b[0m\u001b[3;34m           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mnon-detectable levels of a spironolactone metabolite. Post hoc analyses have limitations, but they suggest a \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpossibility of benefit in appropriately selected patients with symptomatic HFpEF\u001b[0m\u001b[3;34m                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Whelton et al.\u001b[0m\u001b[3;34m                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2017 High Blood Pressure Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# MAY 15, 2018: e127–248\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# TABLE 19\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Intravenous Antihypertensive Drugs for Treatment of Hypertensive Emergencies\u001b[0m\u001b[3;34m                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Class|Drug(s)|Usual Dose Range|Comments|\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|---|\u001b[0m\u001b[3;34m                                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|CCB—dihydropyridines|Nicardipine|Initial 5 mg/h, increasing every 5 min by 2.5 mg/h to maximum 15 \u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmg/h.|Contraindicated in advanced aortic stenosis; no dose adjustment needed for elderly.|\u001b[0m\u001b[3;34m                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m| |Clevidipine|Initial 1–2 mg/h, doubling every 90 s until BP approaches target, then increasing by less than \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdouble every 5–10 min; maximum dose 32 mg/h; maximum duration 72 h.|Contraindicated in patients with soybean, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msoy product, egg, and egg product allergy and in patients with defective lipid metabolism (e.g., pathological \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhyperlipidemia, lipoid nephrosis or acute pancreatitis). Use low-end dose range for elderly patients.|\u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Vasodilators—Nitric-oxide dependent|Sodium nitroprusside|Initial 0.3–0.5 mcg/kg/min; increase in increments of\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m0.5 mcg/kg/min to achieve BP target; maximum dose 10 mcg/kg/min; duration of treatment as short as possible. \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mFor infusion rates ≥4–10 mcg/kg/min or duration >30 min, thiosulfate can be coadministered to prevent cyanide \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtoxicity.|Intra-arterial BP monitoring recommended to prevent “overshoot.” Lower dosing adjustment required for\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34melderly. Tachyphylaxis common with extended use. Cyanide toxicity with prolonged use can result in irreversible\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mneurological changes and cardiac arrest.|\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m| |Nitroglycerin|Initial 5 mcg/min; increase in increments of 5 mcg/min every 3–5 min to a maximum of 20 \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmcg/min.|Use only in patients with acute coronary syndrome and/or acute pulmonary edema. Do not use in \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mvolume-depleted patients.|\u001b[0m\u001b[3;34m                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Vasodilators—direct|Hydralazine|Initial 10 mg via slow IV infusion (maximum initial dose 20 mg); repeat every \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4–6 h as needed.|BP begins to decrease within 10–30 min, and the fall lasts 2–4 h. Unpredictability of response\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand prolonged duration of action do not make hydralazine a desirable first-line agent for acute treatment in \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmost patients.|\u001b[0m\u001b[3;34m                                                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Adrenergic blockers—beta1 receptor selective antagonist|Esmolol|Loading dose 500–1000 mcg/kg/min over 1 min \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfollowed by a 50-mcg/kg/min infusion. For additional dosing, the bolus dose is repeated and the infusion \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mincreased in 50-mcg/kg/min increments as needed to a maximum of 200 mcg/kg/min.|Contraindicated in patients \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwith concurrent beta-blocker therapy, bradycardia, or decompensated HF. Monitor for bradycardia. May worsen HF.\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHigher doses may block beta2 receptors and impact lung function in reactive airway disease.|\u001b[0m\u001b[3;34m                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Adrenergic blockers—combined alpha1 and nonselective beta receptor antagonist|Labetalol|Initial 0.3–1.0-mg/kg \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdose (maximum 20 mg) slow IV injection every 10 min or 0.4–1.0-mg/kg/h IV infusion up to 3 mg/kg/h. Adjust rate\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mup to total cumulative dose of 300 mg. This dose can be repeated every 4–6 h.|Contraindicated in reactive \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mairways disease or chronic obstructive pulmonary disease. Especially useful in hyperadrenergic syndromes. May \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mworsen HF and should not be given in patients with second- or third-degree heart block or bradycardia.|\u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Adrenergic blockers—nonselective alpha receptor antagonist|Phentolamine|IV bolus dose 5 mg. Additional bolus \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdoses every 10 min as needed to lower BP to target.|Used in hypertensive emergencies induced by catecholamine \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mexcess (pheochromocytoma, interactions between monoamine oxidase inhibitors and other drugs or food, cocaine \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtoxicity, amphetamine overdose, or clonidine withdrawal).|\u001b[0m\u001b[3;34m                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Dopamine-receptor1 selective agonist|Fenoldopam|Initial 0.1–0.3\u001b[0m\u001b[3;34m                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m\"first-line\" medication choices|\u001b[0m\u001b[3;34m                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|ACE inhibitor intolerant| |\u001b[0m\u001b[3;34m                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Yes|ARB *|\u001b[0m\u001b[3;34m                                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|No|ACF inhibitor|\u001b[0m\u001b[3;34m                                                                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mColors correspond to Class of Recommendation in Table 1. *CKD stage 3 or higher or stage 1 or 2 with \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34malbuminuria ≥300 mg/d or ≥300 mg/g creatinine. ACE indicates angiotensin-converting enzyme; ARB, angiotensin \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreceptor blocker; BP blood pressure; and CKD, chronic kidney disease.\u001b[0m\u001b[3;34m                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAn ACE inhibitor (or an ARB, in case of ACE inhibitor intolerance) is a preferred drug for treatment of \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypertension if albuminuria (≥300 mg/day or ≥300 mg/g creatinine by first morning void) is present, although \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthe evidence is mixed (S9.3-10,S9.3-11) (Figure 6). In the course of reducing intraglomerular pressure and \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthereby reducing albuminuria, serum creatinine may increase up to 30% because of concurrent reduction in GFR \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S9.3-32). Further GFR decline should be investigated and may be related to other factors, including volume \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcontraction, use of nephrotoxic agents, or renovascular disease (S9.3-33). The combination of an ACE inhibitor \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand an ARB should be avoided because of reported harms demonstrated in several large cardiology trials \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S9.3-34,S9.3-35) and in 1 diabetic nephropathy trial (S9.3-36). Because of the greater risk of hyperkalemia \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand hypotension and lack of...\u001b[0m\u001b[3;34m                                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Whelton et al. e173\u001b[0m\u001b[3;34m                                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# M A Y 1 5 , 2 0 1 8 : e 1 2 7 – 2 4 8\u001b[0m\u001b[3;34m                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2017 High Blood Pressure Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCompelling indications for treatment of SIHD, these drugs are recommended as a first-line therapy in the \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtreatment of hypertension when it occurs in patients with SIHD. GDMT beta blockers for SIHD that are also \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34meffective in lowering BP include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpropranolol, and timolol. Atenolol is not as effective as other antihypertensive drugs in the treatment of \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypertension (S9.1-23).\u001b[0m\u001b[3;34m                                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mDihydropyridine CCBs are effective antianginal drugs that can lower BP and relieve angina pectoris when added \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mto beta blockers in patients in whom hypertension is present and angina pectoris persists despite beta-blocker \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtherapy (S9.1-8,S9.1-17,S9.1-19—S9.1-22,S9.1-24,S9.1-25). GDMT beta blockers for SIHD that are also effective \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34min lowering BP include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, propranolol,\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand timolol.\u001b[0m\u001b[3;34m                                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mIn randomized long-term trials, use of beta blockers after MI reduced all-cause mortality by 23% (S9.1-13). \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mGiven the established efficacy of beta blockers for treating hypertension and SIHD, their use for treatment \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcontinuing beyond 3 years after MI is reasonable (S9.1-6,S9.1-25).\u001b[0m\u001b[3;34m                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mGDMT beta blockers and CCBs are effective antihypertensive and antianginal agents. CCBs include dihydropyridine\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand nondihydropyridine agents. CCBs can be used separately or together with beta blockers beginning 3 years \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mafter MI in patients with CAD who have both hypertension and angina.\u001b[0m\u001b[3;34m                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 9.2. Heart Failure\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation for Prevention of HF in Adults With Hypertension\u001b[0m\u001b[3;34m                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferences that support the recommendation are summarized in Online Data Supplement 33.\u001b[0m\u001b[3;34m                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATION|\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|SBP: B-R|I|In adults at increased risk of HF, the optimal BP in those with hypertension should be less than \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m130/80 mm Hg (S9.2-1—S9.2-3).|\u001b[0m\u001b[3;34m                                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|DBP: C-EO| | |\u001b[0m\u001b[3;34m                                                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Synopsis\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAntecedent hypertension is present in 75% of patients with chronic HF (S9.2-4). In the Cardiovascular Health \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mStudy (S9.2-5) and the Health, Aging and Body Composition Study (S9.2-6), 11.2% of 4408 persons (53.1% women, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwith a mean age of 72.8 years, living in the community, and not receiving antihypertensive drugs at baseline) \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdeveloped HF over 10 years (S9.2-7). Compared with those with an average SBP <120 mm Hg, the adjusted incidence\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof HF was increased 1.6, 2.2, and 2.6 times in those with average SBPs between 120 and 139 mm Hg, between 140 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand 159 mm Hg, and ≥160 mm Hg, respectively (S9.2-7).\u001b[0m\u001b[3;34m                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNo RCTs are available that compare one BP-lowering agent to another for the management of patients with HF. The\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfollowing recommendations for treatment of hypertension in HF are based on use of drugs that lower BP and also \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhave compelling indications for management of HF (with HFrEF or HFpEF) as recommended in current ACC/AHA \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mguidelines (S9.2-4,S9.2-8).\u001b[0m\u001b[3;34m                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation-Specific Supportive Text\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. In adults with hypertension (SBP ≥130 mm Hg or DBP ≥80 mm Hg) and a high risk of CVD, a strong \u001b[0m\u001b[3;34m             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mrecommendation for BP lowering (<130 mm Hg) is higher than that used in SPRINT.\u001b[0m\u001b[3;34m                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mor diltiazem are recommended, with the choice of agents according to patient preferences and comorbid \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mconditions.|\u001b[0m\u001b[3;34m                                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|2a|C-LD|In patients with HCM and subclinical AF detected by internal or external device or monitor, of >5 \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mminutes’ duration but <24 hours’ duration for a given episode, anticoagulation with DOACs as first-line option \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand vitamin K antagonists as second-line option can be beneficial, taking into consideration duration of AF \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mepisodes, total AF burden, underlying risk factors, and bleeding risk.|\u001b[0m\u001b[3;34m                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|2a|B-NR|In patients with HCM and poorly tolerated AF, a rhythm-control strategy with cardioversion or \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mantiarrhythmic drugs can be beneficial with the choice of an agent according to AF symptom severity, patient \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpreferences, and comorbid conditions.|\u001b[0m\u001b[3;34m                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|2a|B-NR|In patients with HCM and symptomatic AF, as part of an AF rhythm-control strategy, catheter ablation \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfor AF can be effective when drug therapy is ineffective, contraindicated, or not the patient’s preference.|\u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|2a|B-NR|In patients with HCM and AF who require surgical myectomy, concomitant surgical AF ablation procedure \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcan be beneficial for AF rhythm control.|\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 71, N O . 1 9, 2 0 1 8\u001b[0m\u001b[3;34m                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Whelton et al. e169\u001b[0m\u001b[3;34m                                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# M A Y 1 5, 2 0 1 8 : e 1 2 7 – 2 4 8\u001b[0m\u001b[3;34m                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2017 High Blood Pressure Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msignificantly better than CCBs for prevention of HF. There were some other nonsignificant differences between \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdiuretics, ACE inhibitors, ARBs, and CCBs, but the general pattern was for similarity in effect. As indicated \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34min Section 8.1.6.1, most adults with hypertension require >1 drug to control their BP. As recommended in \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSection 10.1, for black adults with hypertension (without HF or CKD), initial antihypertensive treatment should\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34minclude a thiazide diuretic or CCB.\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 8.1.6.1. Choice of Initial Monotherapy Versus Initial Combination Drug Therapy\u001b[0m\u001b[3;34m                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|C-EO|Initiation of antihypertensive drug therapy with 2 first-line agents of different classes, either as \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mseparate agents or in a fixed-dose combination, is recommended in adults with stage 2 hypertension and an \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34maverage BP more than 20/10 mm Hg above their BP target.|\u001b[0m\u001b[3;34m                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|C-EO|Initiation of antihypertensive drug therapy with a single antihypertensive drug is reasonable in \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34madults with stage 1 hypertension and BP goal <130/80 mm Hg with dosage titration and sequential addition of \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mother agents to achieve the BP target.|\u001b[0m\u001b[3;34m                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m*Fixed-dose combination antihypertensive medications are listed in Online Data Supplement D.\u001b[0m\u001b[3;34m                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Synopsis\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSystematic review of the evidence comparing the initiation of antihypertensive treatment with monotherapy and \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msequential (stepped-care) titration of additional agents versus initiation of treatment with combination \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtherapy (including fixed-dose combinations) did not identify any RCTs meeting the systematic review questions \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mposed in the PICOTS format (P¼population, I¼intervention, C¼comparator, O¼outcome, T¼timing, S¼setting). \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHowever, in both ACCORD and SPRINT, 2-drug therapy was recommended for most participants in the intensive- but \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mnot standard-therapy groups.\u001b[0m\u001b[3;34m                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation-Specific Supportive Text\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Because most patients with hypertension require multiple agents for control of their BP and those with \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhigher BPs are at greater risk, more rapid titration of antihypertensive medications began to be recommended in\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpatients with BP >20/10 mm Hg above their target, beginning with the JNC 7 report (S8.1.6.1-1). In these \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpatients, initiation of antihypertensive therapy with 2 agents is recommended. Evidence favoring this approach \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcomes mostly from studies using fixed-dose combination products showing greater BP lowering with fixed-dose \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcombination agents than with single agents, as well as better adherence to therapy (S8.1.6.1-2,S8.1.6.1-3). The\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msafety and efficacy of this strategy have been demonstrated in adults to reduce BPs to <140/90 mm Hg though not\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcompared with other strategies (S8.1.6.1-4—S8.1.6.1-6). In general, this approach is reasonable in older \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34madults, those at high CVD risk, or those who have a history of hypotension or drug-associated side effects. \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHowever, caution is advised in initiating antihypertensive pharmacotherapy with 2 drugs in older patients \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbecause hypotension or orthostatic hypotension may develop in some patients; BP should be carefully monitored.\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. The stepped-care approach defined by the initiation of antihypertensive drug therapy with a single agent \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfollowed by the sequential titration of the dose and addition of other agents has been the recommended \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtreatment strategy since the first report of the National High Blood Pressure Education Program (S8.1.6.1-7). \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThis approach is also reasonable in older adults or those at risk or who have a history of hypotension or \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdrug-associated side effects. This strategy has been used successfully in nearly all hypertension treatment \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtrials but has not been formally tested against other antihypertensive drug treatment strategies for \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34meffectiveness in achieving BP control or in preventing adverse outcomes.\u001b[0m\u001b[3;34m                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 8.2. Achieving BP Control in Individual Patients\u001b[0m\u001b[3;34m                                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mRecommendations for lifestyle modifications and drug selection are specified in\u001b[0m\u001b[3;34m                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtherapy should be assessed within 3 to 6 months.\u001b[0m\u001b[3;34m                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. Nonpharmacological therapy can help reduce BP in patients with stage 1 hypertension with an estimated \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m10-year ASCVD risk of ≥10% and should be used in addition to pharmacological therapy as first-line therapy in \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msuch patients (see Section 6.2).\u001b[0m\u001b[3;34m                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m3. Prompt evaluation and treatment of patients with stage 2 hypertension with a combination of drug and \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mnon-pharmacological therapy are important because of the elevated risk of CVD events in this subgroup, \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mespecially those with multiple ASCVD risk factors or target organ damage (S8.1.3-1,S8.1.3-2).\u001b[0m\u001b[3;34m                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4. Prompt management of very high BP is important to reduce the risk of target organ damage (see Section 11.2).\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe rapidity of the treatment needed is dependent on the patient’s clinical presentation (presence of new or \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mworsening target organ damage) and presence or absence of CVD complications, but treatment should be initiated \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwithin at least 1 week.\u001b[0m\u001b[3;34m                                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Whelton et al.\u001b[0m\u001b[3;34m                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2017 High Blood Pressure Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# M A Y  1 5 , 2 0 1 8 : e 1 2 7 – 2 4 8\u001b[0m\u001b[3;34m                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 9.1. Stable Ischemic Heart Disease\u001b[0m\u001b[3;34m                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendations for Treatment of Hypertension in Patients With Stable Ischemic Heart Disease (SIHD)\u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferences that support recommendations are summarized in Online Data Supplements 30-32.\u001b[0m\u001b[3;34m                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|SBP: B-R|I|1. In adults with SIHD and hypertension, a BP target of less than 130/80 mm Hg is recommended \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S9.1-1—S9.1-5).|\u001b[0m\u001b[3;34m                                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|DBP: C-EO| | |\u001b[0m\u001b[3;34m                                                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|SBP: B-R|I|2. Adults with SIHD and hypertension (BP ≥130/80 mm Hg) should be treated with medications (e.g., \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mGDMT beta blockers, ACE inhibitors, or ARBs) for compelling indications (e.g., previous MI, stable angina) as \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfirst-line therapy, with the addition of other drugs (e.g., dihydropyridine CCBs, thiazide diuretics, and/or \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmineralocorticoid receptor antagonists) as needed to further control hypertension (S9.1-6) (S9.1-7—S9.1-10).|\u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m| |B-NR|3. In adults with SIHD with angina and persistent uncontrolled hypertension, the addition of \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdihydropyridine CCBs to GDMT (S9.1-6) beta blockers is recommended (S9.1-8,S9.1-11,S9.1-12).|\u001b[0m\u001b[3;34m                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m| |IIa|4. In adults who have had a MI or acute coronary syndrome, it is reasonable to continue GDMT (S9.1-6) \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbeta blockers beyond 3 years as long-term therapy for hypertension (S9.1-13,S9.1-14).|\u001b[0m\u001b[3;34m                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m| |IIb|5. Beta blockers and/or CCBs might be considered to control hypertension in patients with CAD (without \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHFrEF) who had an MI more than 3 years ago and have angina.|\u001b[0m\u001b[3;34m                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Synopsis\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHypertension is a major risk factor for ischemic heart disease. Numerous RCTs have demonstrated the benefits of\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mantihypertensive drug therapy in reducing the risk of ischemic heart disease. The following recommendations \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mapply only to management of hypertension in patients with SIHD without HF. See Section 9.2 for recommendations \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfor the treatment of patients with SIHD and HF.\u001b[0m\u001b[3;34m                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mFigure 5 is an algorithm on management of hypertension in patients with SIHD.\u001b[0m\u001b[3;34m                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation-Specific Supportive Text\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. In patients with increased cardiovascular risk, reduction of SBP to <130/80 mm Hg has been shown to reduce \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCVD complications by 25% and all-cause mortality by 27% (S9.1-1).\u001b[0m\u001b[3;34m                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. After 5 years of randomized therapy in high-CVD-risk patients, ramipril produced a 22% reduction in MI, \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstroke, or CVD compared with placebo (S9.1-10). No added benefit on CVD outcomes was seen when compared with \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCCBs and diuretics (S9.1-15,S9.1-16). After 4.2 years of randomized therapy in patients with SIHD, perindopril \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduced CVD death, MI, or cardiac arrest by 20% compared with placebo (S9.1-7). Beta blockers are effective \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdrugs for preventing angina pectoris, improving exercise time until the onset of angina pectoris, reducing \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mexercise-induced ischemic ST-segment depression, and preventing coronary events (S9.1-8,S9.1-17—S9.1-22).\u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# F I G U R E 5 Management of Hypertension in Patients With SIHD\u001b[0m\u001b[3;34m                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHypertension With SIHD\u001b[0m\u001b[3;34m                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReduce BP to <130/80 mm Hg with GDMT beta blockers, ACE inhibitor, or ARBs (Class I)\u001b[0m\u001b[3;34m                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mBP goal not met\u001b[0m\u001b[3;34m                                                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAngina pectoris\u001b[0m\u001b[3;34m                                                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNo\u001b[0m\u001b[3;34m                                                                                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAdd dihydropyridine CCBs if needed (Class I)\u001b[0m\u001b[3;34m                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAdd dihydropyridine CCBs; thiazide-type\u001b[0m\u001b[3;34m                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Whelton et al. e163\u001b[0m\u001b[3;34m                                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# M A Y 1 5 , 2 0 1 8 : e 1 2 7 – 2 4 8\u001b[0m\u001b[3;34m                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2017 High Blood Pressure Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mrisk of CVD (S8.1.2-12,S8.1.2-13). Indirect support is also provided by evidence from trials using BP-lowering \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmedications to reduce the risk of developing higher levels of BP (S8.1.2-59—S8.1.2-61) and, in one case, to \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34machieve a reduction in LV mass (S8.1.2-62). In the HOPE-3 (Heart Outcomes Prevention Evaluation-3) BP Trial, \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthere was no evidence of short-term benefit during treatment of adults (average age 66 years) with a relatively\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlow risk of CVD (3.8% CVD event rate during 5.6 years of follow-up). However, subgroup analysis suggested \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbenefit in those with an average SBP approximately >140 mm Hg (and a CVD risk of 6.5% during the 5.6 years of \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfollow-up) (S8.1.2-63). We acknowledge the importance of excluding white coat hypertension before initiating \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpharmacological therapy in hypertensive patients with low ASCVD risk. This may be accomplished (as described in\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSection 4) by HBPM or ABPM as appropriate.\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 8.1.3. Follow-Up After Initial BP Evaluation\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendations for Follow-Up After Initial BP Evaluation\u001b[0m\u001b[3;34m                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferences that support recommendations are summarized in Online Data Supplement 24.\u001b[0m\u001b[3;34m                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-R|Adults with an elevated BP or stage 1 hypertension who have an estimated 10-year ASCVD risk less than \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m10% should be managed with nonpharmacological therapy and have a repeat BP evaluation within 3 to 6 months \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S8.1.3-1,S8.1.3-2).|\u001b[0m\u001b[3;34m                                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-R|Adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of 10% or higher should be \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmanaged initially with a combination of nonpharmacological and antihypertensive drug therapy and have a repeat \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mBP evaluation in 1 month (S8.1.3-1,S8.1.3-2).|\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-R|Adults with stage 2 hypertension should be evaluated by or referred to a primary care provider within 1 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmonth of the initial diagnosis, have a combination of nonpharmacological and antihypertensive drug therapy \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(with 2 agents of different classes) initiated, and have a repeat BP evaluation in 1 month \u001b[0m\u001b[3;34m                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S8.1.3-1,S8.1.3-2).|\u001b[0m\u001b[3;34m                                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-R|For adults with a very high average BP (e.g., SBP ≥180 mm Hg or DBP ≥110 mm Hg), evaluation followed by \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mprompt antihypertensive drug treatment is recommended (S8.1.3-1,S8.1.3-2).|\u001b[0m\u001b[3;34m                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|C-EO|For adults with a normal BP, repeat evaluation every year is reasonable.|\u001b[0m\u001b[3;34m                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Synopsis\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAn important component of BP management in hypertensive patients is follow-up. Different periods of time for \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfollow-up are recommended depending on the stage of hypertension, the presence or absence of target organ \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdamage, treatment with antihypertensive medications, and the level of BP control. Recommendations for follow-up\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mare summarized in Figure 4.\u001b[0m\u001b[3;34m                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation-Specific Supportive Text\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Nonpharmacological therapy (see Section 6.2) is the preferred therapy for adults with elevated BP and an \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mappropriate first-line therapy for adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m<10%. Adherence to and impact of non-pharmacological therapy should be assessed within 3 to 6 months.\u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. Nonpharmacological therapy can help reduce BP in patients with stage 1 hypertension with an estimated \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m10-year ASCVD risk of ≥10% and should be used in addition to pharmacological therapy as first-line therapy in \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msuch patients (see Section 6.2).\u001b[0m\u001b[3;34m                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m3. Prompt evaluation and treatment of patients with stage 2 hypertension with a combination of drug and \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mnon-pharmacological therapy are important because of the elevated risk of CVD\u001b[0m\u001b[3;34m                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content=\"According to the ACC guidelines for the    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ management of hypertension in elderly patients, the first-line therapy options include:\\n\\n1. **Thiazide        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Diuretics** - These are often recommended for their effectiveness in lowering blood pressure and providing      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ benefits in reducing heart failure risk.\\n2. **Calcium Channel Blockers (CCBs)** - These can be utilized as     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ first-line agents, especially in patients with specific comorbid conditions that warrant their use.\\n3.         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ **Angiotensin-Converting Enzyme (ACE) Inhibitors** or **Angiotensin Receptor Blockers (ARBs)** - These are also │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ considered for initial treatment, particularly in patients with conditions such as heart failure or chronic     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ kidney disease that may benefit from them.\\n\\nThe guidelines emphasize that the choice of therapy should take   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ into account the patient's overall health status, comorbidities, and the potential for side effects, especially │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ in older adults who may be more vulnerable to hypotension and orthostatic changes. \\n\\nIn practice, many        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients will require more than one medication to effectively manage their blood pressure, particularly those   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with stage 2 hypertension (BP &gt;20/10 mm Hg above target). In such cases, initiating therapy with two agents is  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ recommended.\", refusal=None, role='assistant', audio=None, function_call=None, tool_calls=None)                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content=\"According to the ACC guidelines for the \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmanagement of hypertension in elderly patients, the first-line therapy options include:\\n\\n1. **Thiazide \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mDiuretics** - These are often recommended for their effectiveness in lowering blood pressure and providing \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbenefits in reducing heart failure risk.\\n2. **Calcium Channel Blockers (CCBs)** - These can be utilized as \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfirst-line agents, especially in patients with specific comorbid conditions that warrant their use.\\n3. \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m**Angiotensin-Converting Enzyme (ACE) Inhibitors** or **Angiotensin Receptor Blockers (ARBs)** - These are also\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mconsidered for initial treatment, particularly in patients with conditions such as heart failure or chronic \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mkidney disease that may benefit from them.\\n\\nThe guidelines emphasize that the choice of therapy should take \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minto account the patient's overall health status, comorbidities, and the potential for side effects, especially\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2min older adults who may be more vulnerable to hypotension and orthostatic changes. \\n\\nIn practice, many \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients will require more than one medication to effectively manage their blood pressure, particularly those \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith stage 2 hypertension (BP >20/10 mm Hg above target). In such cases, initiating therapy with two agents is \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrecommended.\", refusal=None, role='assistant', audio=None, function_call=None, tool_calls=None)\u001b[0m\u001b[2m                \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> According to the ACC guidelines for the management of hypertension in elderly patients, the first-line therapy  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> options include:                                                                                                </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 1. **Thiazide Diuretics** - These are often recommended for their effectiveness in lowering blood pressure and  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> providing benefits in reducing heart failure risk.                                                              </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 2. **Calcium Channel Blockers (CCBs)** - These can be utilized as first-line agents, especially in patients     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> with specific comorbid conditions that warrant their use.                                                       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 3. **Angiotensin-Converting Enzyme (ACE) Inhibitors** or **Angiotensin Receptor Blockers (ARBs)** - These are   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> also considered for initial treatment, particularly in patients with conditions such as heart failure or        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> chronic kidney disease that may benefit from them.                                                              </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> The guidelines emphasize that the choice of therapy should take into account the patient's overall health       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> status, comorbidities, and the potential for side effects, especially in older adults who may be more           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> vulnerable to hypotension and orthostatic changes.                                                              </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> In practice, many patients will require more than one medication to effectively manage their blood pressure,    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> particularly those with stage 2 hypertension (BP &gt;20/10 mm Hg above target). In such cases, initiating therapy  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> with two agents is recommended.                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mAccording to the ACC guidelines for the management of hypertension in elderly patients, the first-line therapy \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32moptions include:\u001b[0m\u001b[1;32m                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m1. **Thiazide Diuretics** - These are often recommended for their effectiveness in lowering blood pressure and \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mproviding benefits in reducing heart failure risk.\u001b[0m\u001b[1;32m                                                             \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m2. **Calcium Channel Blockers (CCBs)** - These can be utilized as first-line agents, especially in patients \u001b[0m\u001b[1;32m   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mwith specific comorbid conditions that warrant their use.\u001b[0m\u001b[1;32m                                                      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m3. **Angiotensin-Converting Enzyme (ACE) Inhibitors** or **Angiotensin Receptor Blockers (ARBs)** - These are \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32malso considered for initial treatment, particularly in patients with conditions such as heart failure or \u001b[0m\u001b[1;32m      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mchronic kidney disease that may benefit from them.\u001b[0m\u001b[1;32m                                                             \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mThe guidelines emphasize that the choice of therapy should take into account the patient's overall health \u001b[0m\u001b[1;32m     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mstatus, comorbidities, and the potential for side effects, especially in older adults who may be more \u001b[0m\u001b[1;32m         \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mvulnerable to hypotension and orthostatic changes. \u001b[0m\u001b[1;32m                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mIn practice, many patients will require more than one medication to effectively manage their blood pressure, \u001b[0m\u001b[1;32m  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mparticularly those with stage 2 hypertension (BP >20/10 mm Hg above target). In such cases, initiating therapy \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mwith two agents is recommended.\u001b[0m\u001b[1;32m                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "user_question_1 = \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"\n",
    "run_multi_step_agent(user_question_1)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant',       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ audio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_P5iQgDKmhzYwP9hKfIlOeLxp',   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\":\"2025 new anticoagulant therapies FDA updates\"}', name='search_bing'),    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ type='function')])                                                                                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant', \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maudio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_P5iQgDKmhzYwP9hKfIlOeLxp', \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\":\"2025 new anticoagulant therapies FDA updates\"}', name='search_bing'), \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtype='function')])\u001b[0m\u001b[2m                                                                                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: search_bing                                                                        │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: search_bing\u001b[0m\u001b[1;35m                                                                       \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\":\"2025 new anticoagulant therapies FDA updates\"}                         │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\":\"2025 new anticoagulant therapies FDA updates\"}\u001b[0m\u001b[35m                        \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': '2025 new anticoagulant therapies FDA updates'}          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': '2025 new anticoagulant therapies FDA updates'}\u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_bing                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"2025 new anticoagulant therapies FDA updates\"                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_bing\u001b[0m\u001b[1;34m                                                                         \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"2025 new anticoagulant therapies FDA updates\"\u001b[0m\u001b[1;34m                                                      \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: search_bing with args: {'query': '2025 new anticoagulant therapies │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ FDA updates'}                                                                                                   │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: search_bing with args: {'query': '2025 new anticoagulant therapies\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mFDA updates'}\u001b[0m\u001b[1;35m                                                                                                  \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ Tool Invoked: Bing Search                                                                                       │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ Query: 2025 new anticoagulant therapies FDA updates                                                             │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mTool Invoked: Bing Search\u001b[0m\u001b[1;35m                                                                                      \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mQuery: 2025 new anticoagulant therapies FDA updates\u001b[0m\u001b[1;35m                                                            \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output: No. Drug Name Active Ingredient Approval Date FDA-approved use on approval date* │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 5. Romvimza: vimseltinib: 2/14/2025: To treat symptomatic tenosynovial giant cell tumor for which surgical    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ...                                                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Thrombosis is a potentially fatal condition for which various anticoagulant therapies have been used for    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ prevention and treatment. However, bleeding events remain a concern with all anticoagulant drugs. ...       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Development of new anticoagulants targeting coagulation factor XI and prospects for clinical use ... 2025 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Feb 13:S0914-5087(25)00061-9. doi ...                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Grafapex (treosulfan) Lyophilized Powder for Injection. Company: Medexus Pharmaceuticals Inc. Date of Approval: │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ January 21, 2025 Treatment for: Stem Cell Transplant Conditioning Grafapex (treosulfan) is an alkylating    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ agent indicated in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ transplantation in adult and pediatric patients one year of age and ...                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals.  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Summary: Selected drug approvals anticipated in the 12-month period covering the fourth quarter of 2024 through │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ the third quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and financial ...                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Researchers have reported that a drug representing a new class of anticoagulants showed an “overwhelming”   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduction in bleeding events compared with standard-of-care treatment in patients with atrial fibrillation    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (AF). Results of the phase II ‘AZALEA-TIMI 71’ study, published in the New England Journal of Medicine on 22  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ January 2025, showed that the monoclonal antibody abelacimab […]                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The FDA has several new drug applications on its plate, targeting the treatment of Alzheimer’s,           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Parkinson’s, bipolar depression, migraine, and more. ... in adults with advanced Parkinson’s disease,           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ subcutaneous (NDA resubmitted; Update: FDA approved on February 4, 2025) AXS-07 (Symbravo/Axsome          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Therapeutics) for Migraine: A novel, oral ...                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The rapid evolution of amyloidosis treatment is ushering in an era of precision medicine. Experimental        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ therapies like CRISPR-Cas 9 gene editing and monoclonal antibodies promise targeted interventions with        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ transformative potential. However, challenges remain, including high drug costs and disparities in diagnosis    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and treatment access.                                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The newly developed factor XIa and XIIa inhibitors have the potential to address these unmet clinical needs and │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ are undergoing clinical evaluation for several indications. SIGNIFICANCE STATEMENT: Anticoagulant therapy   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ is the cornerstone of treatment and prevention of thrombosis, which remains a leading cause of morbidity and  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mortality worldwide.                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ This has led to the concept of targeting FXI/FXIa as an anticoagulant strategy. Proof of concept is supported │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ by 20 years of animal model data. Strategies include parenteral monoclonal antibodies to decrease FXI and FXIa  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ levels, antisense oligonucleotides, as well as oral small molecule inhibitors of FXIa. 1                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ New tablet formulation may provide greater freedom and independence for people with SMA thanks to simplified  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ dose administration Basel, 12 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi®           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (risdiplam) tablet for people living with spinal muscular atrophy (SMA).                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output: No. Drug Name Active Ingredient Approval Date FDA-approved use on approval date*\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m5. Romvimza: vimseltinib: 2/14/2025: To treat symptomatic tenosynovial giant cell tumor for which surgical \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m...\u001b[0m\u001b[3;34m                                                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThrombosis is a potentially fatal condition for which various anticoagulant therapies have been used for \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mprevention and treatment. However, bleeding events remain a concern with all anticoagulant drugs. ... \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mDevelopment of new anticoagulants targeting coagulation factor XI and prospects for clinical use ... 2025\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mFeb 13:S0914-5087(25)00061-9. doi ...\u001b[0m\u001b[3;34m                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mGrafapex (treosulfan) Lyophilized Powder for Injection. Company: Medexus Pharmaceuticals Inc. Date of Approval:\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mJanuary 21, 2025 Treatment for: Stem Cell Transplant Conditioning Grafapex (treosulfan) is an alkylating \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34magent indicated in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtransplantation in adult and pediatric patients one year of age and ...\u001b[0m\u001b[3;34m                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThis article aims to support pharmacists by providing updates on new and anticipated novel drug approvals. \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSummary: Selected drug approvals anticipated in the 12-month period covering the fourth quarter of 2024 through\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthe third quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand financial ...\u001b[0m\u001b[3;34m                                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mResearchers have reported that a drug representing a new class of anticoagulants showed an “overwhelming” \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduction in bleeding events compared with standard-of-care treatment in patients with atrial fibrillation \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(AF). Results of the phase II ‘AZALEA-TIMI 71’ study, published in the New England Journal of Medicine on 22 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mJanuary 2025, showed that the monoclonal antibody abelacimab […]\u001b[0m\u001b[3;34m                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe FDA has several new drug applications on its plate, targeting the treatment of Alzheimer’s, \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mParkinson’s, bipolar depression, migraine, and more. ... in adults with advanced Parkinson’s disease, \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msubcutaneous (NDA resubmitted; Update: FDA approved on February 4, 2025) AXS-07 (Symbravo/Axsome \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTherapeutics) for Migraine: A novel, oral ...\u001b[0m\u001b[3;34m                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe rapid evolution of amyloidosis treatment is ushering in an era of precision medicine. Experimental \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtherapies like CRISPR-Cas 9 gene editing and monoclonal antibodies promise targeted interventions with \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtransformative potential. However, challenges remain, including high drug costs and disparities in diagnosis \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand treatment access.\u001b[0m\u001b[3;34m                                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe newly developed factor XIa and XIIa inhibitors have the potential to address these unmet clinical needs and\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mare undergoing clinical evaluation for several indications. SIGNIFICANCE STATEMENT: Anticoagulant therapy \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mis the cornerstone of treatment and prevention of thrombosis, which remains a leading cause of morbidity and \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmortality worldwide.\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThis has led to the concept of targeting FXI/FXIa as an anticoagulant strategy. Proof of concept is supported\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mby 20 years of animal model data. Strategies include parenteral monoclonal antibodies to decrease FXI and FXIa \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlevels, antisense oligonucleotides, as well as oral small molecule inhibitors of FXIa. 1\u001b[0m\u001b[3;34m                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNew tablet formulation may provide greater freedom and independence for people with SMA thanks to simplified \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdose administration Basel, 12 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mU.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(risdiplam) tablet for people living with spinal muscular atrophy (SMA).\u001b[0m\u001b[3;34m                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='In 2025, there have been notable updates   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ regarding new anticoagulant therapies, particularly the monoclonal antibody abelacimab, which demonstrated a    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ significant reduction in bleeding events compared to standard treatment in patients with atrial fibrillation    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (AF). The results of the phase II study, known as ‘AZALEA-TIMI 71’, were published on January 22, 2025, and     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ highlighted its potential advantages over conventional therapies.\\n\\nAdditionally, there is ongoing development │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ of novel anticoagulants targeting coagulation factor XI, which may address unmet clinical needs. These new      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ therapies include factor XIa and XIIa inhibitors, with various delivery methods, such as parenteral monoclonal  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ antibodies, antisense oligonucleotides, and oral small molecule inhibitors, being evaluated in clinical         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ studies.\\n\\nOverall, the landscape for anticoagulant treatments is evolving rapidly, with promising newcomers   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ showing potential for enhanced safety and efficacy in managing thrombosis-related conditions.', refusal=None,   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ role='assistant', audio=None, function_call=None, tool_calls=None)                                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='In 2025, there have been notable updates \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mregarding new anticoagulant therapies, particularly the monoclonal antibody abelacimab, which demonstrated a \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msignificant reduction in bleeding events compared to standard treatment in patients with atrial fibrillation \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(AF). The results of the phase II study, known as ‘AZALEA-TIMI 71’, were published on January 22, 2025, and \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhighlighted its potential advantages over conventional therapies.\\n\\nAdditionally, there is ongoing development\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mof novel anticoagulants targeting coagulation factor XI, which may address unmet clinical needs. These new \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtherapies include factor XIa and XIIa inhibitors, with various delivery methods, such as parenteral monoclonal \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mantibodies, antisense oligonucleotides, and oral small molecule inhibitors, being evaluated in clinical \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstudies.\\n\\nOverall, the landscape for anticoagulant treatments is evolving rapidly, with promising newcomers \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mshowing potential for enhanced safety and efficacy in managing thrombosis-related conditions.', refusal=None, \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrole='assistant', audio=None, function_call=None, tool_calls=None)\u001b[0m\u001b[2m                                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> In 2025, there have been notable updates regarding new anticoagulant therapies, particularly the monoclonal     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> antibody abelacimab, which demonstrated a significant reduction in bleeding events compared to standard         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> treatment in patients with atrial fibrillation (AF). The results of the phase II study, known as ‘AZALEA-TIMI   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 71’, were published on January 22, 2025, and highlighted its potential advantages over conventional therapies.  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> Additionally, there is ongoing development of novel anticoagulants targeting coagulation factor XI, which may   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> address unmet clinical needs. These new therapies include factor XIa and XIIa inhibitors, with various delivery </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> methods, such as parenteral monoclonal antibodies, antisense oligonucleotides, and oral small molecule          </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> inhibitors, being evaluated in clinical studies.                                                                </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> Overall, the landscape for anticoagulant treatments is evolving rapidly, with promising newcomers showing       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> potential for enhanced safety and efficacy in managing thrombosis-related conditions.                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mIn 2025, there have been notable updates regarding new anticoagulant therapies, particularly the monoclonal \u001b[0m\u001b[1;32m   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mantibody abelacimab, which demonstrated a significant reduction in bleeding events compared to standard \u001b[0m\u001b[1;32m       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mtreatment in patients with atrial fibrillation (AF). The results of the phase II study, known as ‘AZALEA-TIMI \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m71’, were published on January 22, 2025, and highlighted its potential advantages over conventional therapies.\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mAdditionally, there is ongoing development of novel anticoagulants targeting coagulation factor XI, which may \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32maddress unmet clinical needs. These new therapies include factor XIa and XIIa inhibitors, with various delivery\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mmethods, such as parenteral monoclonal antibodies, antisense oligonucleotides, and oral small molecule \u001b[0m\u001b[1;32m        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32minhibitors, being evaluated in clinical studies.\u001b[0m\u001b[1;32m                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mOverall, the landscape for anticoagulant treatments is evolving rapidly, with promising newcomers showing \u001b[0m\u001b[1;32m     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mpotential for enhanced safety and efficacy in managing thrombosis-related conditions.\u001b[0m\u001b[1;32m                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "user_question_2 = \"Are there any recent updates in 2025 on new anticoagulant therapies from the FDA?\"\n",
    "run_multi_step_agent(user_question_2)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant',       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ audio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_0ORKc1HyJ8v5OHtod3v3lYHx',   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\":\"SELECT COUNT(*) as PatientCount FROM PatientMedicalData WHERE            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ MedicalCondition LIKE \\'%Hypertension%\\' AND Medications LIKE \\'%Lisinopril%\\'\"}', name='lookup_patient_data'), │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ type='function')])                                                                                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant', \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maudio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_0ORKc1HyJ8v5OHtod3v3lYHx', \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\":\"SELECT COUNT(*) as PatientCount FROM PatientMedicalData WHERE \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMedicalCondition LIKE \\'%Hypertension%\\' AND Medications LIKE \\'%Lisinopril%\\'\"}', name='lookup_patient_data'),\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtype='function')])\u001b[0m\u001b[2m                                                                                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: lookup_patient_data                                                                │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: lookup_patient_data\u001b[0m\u001b[1;35m                                                               \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\":\"SELECT COUNT(*) as PatientCount FROM PatientMedicalData WHERE          │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ MedicalCondition LIKE '%Hypertension%' AND Medications LIKE '%Lisinopril%'\"}                                    │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\":\"SELECT COUNT(*) as PatientCount FROM PatientMedicalData WHERE \u001b[0m\u001b[35m        \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35mMedicalCondition LIKE '%Hypertension%' AND Medications LIKE '%Lisinopril%'\"}\u001b[0m\u001b[35m                                   \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': \"SELECT COUNT(*) as PatientCount FROM PatientMedicalData │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ WHERE MedicalCondition LIKE '%Hypertension%' AND Medications LIKE '%Lisinopril%'\"}                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': \"SELECT COUNT(*) as PatientCount FROM PatientMedicalData\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mWHERE MedicalCondition LIKE '%Hypertension%' AND Medications LIKE '%Lisinopril%'\"}\u001b[0m\u001b[32m                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool lookup_patient_data                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"SELECT COUNT(*) as PatientCount FROM PatientMedicalData WHERE MedicalCondition LIKE                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ '%Hypertension%' AND Medications LIKE '%Lisinopril%'\"                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34mlookup_patient_data\u001b[0m\u001b[1;34m                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"SELECT COUNT(*) as PatientCount FROM PatientMedicalData WHERE MedicalCondition LIKE \u001b[0m\u001b[1;34m               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m'%Hypertension%' AND Medications LIKE '%Lisinopril%'\"\u001b[0m\u001b[1;34m                                                          \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: lookup_patient_data with args: {'query': \"SELECT COUNT(*) as       │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ PatientCount FROM PatientMedicalData WHERE MedicalCondition LIKE '%Hypertension%' AND Medications LIKE          │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ '%Lisinopril%'\"}                                                                                                │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: lookup_patient_data with args: {'query': \"SELECT COUNT(*) as \u001b[0m\u001b[1;35m     \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mPatientCount FROM PatientMedicalData WHERE MedicalCondition LIKE '%Hypertension%' AND Medications LIKE \u001b[0m\u001b[1;35m        \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m'%Lisinopril%'\"}\u001b[0m\u001b[1;35m                                                                                               \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output:  PatientCount                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│          1071                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output:  PatientCount\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m         1071\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='There are 1,071 patients who have          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Hypertension and are prescribed Lisinopril.', refusal=None, role='assistant', audio=None, function_call=None,   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tool_calls=None)                                                                                                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='There are 1,071 patients who have \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHypertension and are prescribed Lisinopril.', refusal=None, role='assistant', audio=None, function_call=None, \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtool_calls=None)\u001b[0m\u001b[2m                                                                                               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> There are 1,071 patients who have Hypertension and are prescribed Lisinopril.                                   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mThere are 1,071 patients who have Hypertension and are prescribed Lisinopril.\u001b[0m\u001b[1;32m                                  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "user_question_3 = \"How many patients have Hypertension and are prescribed Lisinopril?\"\n",
    "# The agent should generate a valid SQL query, for example:\n",
    "## Note, the answer will depend on the actual data in the database (it should return 1071!)\n",
    "run_multi_step_agent(user_question_3)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant',       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ audio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_PoMgQiew09X2gAeYSWpObYII',   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName = \\'Gloria\\' AND       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ LastName = \\'Paul\\'\"}', name='lookup_patient_data'), type='function'),                                          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessageToolCall(id='call_CaajWhmNyJ8is5hxgf9RsYtb', function=Function(arguments='{\"query\":        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \"hyperlipidemia guidelines\"}', name='search_acc_guidelines'), type='function'),                                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessageToolCall(id='call_2ZOnruZOBA9FyrQ3n4OR8c64', function=Function(arguments='{\"query\": \"FDA   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ medication updates hyperlipidemia February 2025\"}', name='search_bing'), type='function')])                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant', \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maudio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_PoMgQiew09X2gAeYSWpObYII', \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName = \\'Gloria\\' AND \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLastName = \\'Paul\\'\"}', name='lookup_patient_data'), type='function'), \u001b[0m\u001b[2m                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessageToolCall(id='call_CaajWhmNyJ8is5hxgf9RsYtb', function=Function(arguments='{\"query\": \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\"hyperlipidemia guidelines\"}', name='search_acc_guidelines'), type='function'), \u001b[0m\u001b[2m                               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessageToolCall(id='call_2ZOnruZOBA9FyrQ3n4OR8c64', function=Function(arguments='{\"query\": \"FDA \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmedication updates hyperlipidemia February 2025\"}', name='search_bing'), type='function')])\u001b[0m\u001b[2m                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: lookup_patient_data                                                                │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: lookup_patient_data\u001b[0m\u001b[1;35m                                                               \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName = 'Gloria' AND       │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ LastName = 'Paul'\"}                                                                                             │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName = 'Gloria' AND \u001b[0m\u001b[35m     \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35mLastName = 'Paul'\"}\u001b[0m\u001b[35m                                                                                            \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': \"SELECT * FROM PatientMedicalData WHERE FirstName =      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 'Gloria' AND LastName = 'Paul'\"}                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': \"SELECT * FROM PatientMedicalData WHERE FirstName = \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m'Gloria' AND LastName = 'Paul'\"}\u001b[0m\u001b[32m                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool lookup_patient_data                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName = 'Gloria' AND LastName = 'Paul'\"                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34mlookup_patient_data\u001b[0m\u001b[1;34m                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName = 'Gloria' AND LastName = 'Paul'\"\u001b[0m\u001b[1;34m                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: lookup_patient_data with args: {'query': \"SELECT * FROM            │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ PatientMedicalData WHERE FirstName = 'Gloria' AND LastName = 'Paul'\"}                                           │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: lookup_patient_data with args: {'query': \"SELECT * FROM \u001b[0m\u001b[1;35m          \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mPatientMedicalData WHERE FirstName = 'Gloria' AND LastName = 'Paul'\"}\u001b[0m\u001b[1;35m                                          \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output:  PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Address        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ SmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ HeartRate_bpm  Temperature_C                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Notes                                                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│          1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Cove\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ year parent. Happen energy level anyone position. Few available thought world development.                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output:  PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAddress        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHeartRate_bpm  Temperature_C                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNotes\u001b[0m\u001b[3;34m                                                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m         1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes \u001b[0m\u001b[3;34m              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCove\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7   \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34myear parent. Happen energy level anyone position. Few available thought world development.\u001b[0m\u001b[3;34m                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: search_acc_guidelines                                                              │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: search_acc_guidelines\u001b[0m\u001b[1;35m                                                             \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\": \"hyperlipidemia guidelines\"}                                           │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\": \"hyperlipidemia guidelines\"}\u001b[0m\u001b[35m                                          \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': 'hyperlipidemia guidelines'}                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': 'hyperlipidemia guidelines'}\u001b[0m\u001b[32m                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_acc_guidelines                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"hyperlipidemia guidelines\"                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_acc_guidelines\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"hyperlipidemia guidelines\"\u001b[0m\u001b[1;34m                                                                         \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: search_acc_guidelines with args: {'query': 'hyperlipidemia         │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ guidelines'}                                                                                                    │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: search_acc_guidelines with args: {'query': 'hyperlipidemia \u001b[0m\u001b[1;35m       \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mguidelines'}\u001b[0m\u001b[1;35m                                                                                                   \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Tool Invoked: ACC Guidelines Search                                                                             │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Query: hyperlipidemia guidelines                                                                                │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mTool Invoked: ACC Guidelines Search\u001b[0m\u001b[1;33m                                                                            \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mQuery: hyperlipidemia guidelines\u001b[0m\u001b[1;33m                                                                               \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output: than in former smokers, and there was a significant relationship between the       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ severity of carotid stenosis and pack-years of exposure to tobacco (239). The RRs of finding 60% carotid        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ stenosis were 1.5 and 3.9 among cigarette smokers with cerebral ischemia in the NOMASS and the BCID (Berlin     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Cerebral Ischemia Databank) studies, respectively (258).                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.3. Control of Hyperlipidemia                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.3.1. Recommendations for Control of Hyperlipidemia                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ CLASS I                                                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Treatment with a statin medication is recommended for all patients with extracranial carotid or vertebral    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ atherosclerosis to reduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Evidence: B)                                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ CLASS IIa                                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or vertebral     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ atherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70 mg/dL (259).  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (Level of Evidence: B)                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. If treatment with a statin (including trials of higher-dose statins and higher-potency statins) does not     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ achieve the goal selected for a patient, intensifying LDL-lowering drug therapy with an additional drug from    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ among those with evidence of improving outcomes (i.e., bile acid sequestrants or niacin) can be effective       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (261–264). (Level of Evidence: B)                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 3. For patients who do not tolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reasonable (261,263,265). (Level of Evidence: B)                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The relationship between cholesterol and ischemic stroke is not as evident as that between cholesterol and MI,  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and findings from population-based studies are inconsistent. In the MR FIT (Multiple Risk Factor Intervention   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Trial), comprising more than 350,000 men, the RR of death increased progressively with serum cholesterol,       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ exceeding 2.5 in those with the highest levels (266). An analysis of 45 prospective observational cohorts       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ involving approximately 450,000 individuals, however, found no association of hypercholesterolemia with stroke  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (267). In the ARIC study, the relationships between lipid values and incident ischemic.                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # e318                                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Grundy et al.                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E  2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.5.2. Hypertriglyceridemia                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendations for Hypertriglyceridemia                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Referenced studies that support recommendations are summarized in Online Data Supplements 31 and 32.            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-NR|In adults 20 years of age or older with moderate hypertriglyceridemia (fasting or nonfasting            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglycerides 175 to 499 mg/dL [2.0 to 5.6 mmol/L]), clinicians should address and treat lifestyle factors      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (obesity and metabolic syndrome), secondary factors (diabetes mellitus, chronic liver or kidney disease and/or  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ nephrotic syndrome, hypothyroidism), and medications that increase triglycerides (S4.5.2-1).|                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In adults 40 to 75 years of age with moderate or severe hypertriglyceridemia and ASCVD risk of 7.5% or │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ higher, it is reasonable to reevaluate ASCVD risk after lifestyle and secondary factors are addressed and to    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ consider a persistently elevated triglyceride level as a factor favoring initiation or intensification of       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ statin therapy (see Section 4.4.2.) (S4.5.2-2—S4.5.2-6).|                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In adults 40 to 75 years of age with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [≥5.6 mmol/L]) and ASCVD risk of 7.5% or higher, it is reasonable to address reversible causes of high          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglyceride and to initiate statin therapy (S4.5.2-3—S4.5.2-5, S4.5.2-7, S4.5.2-8).|                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-NR|In adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L]), and      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ especially fasting triglycerides ≥1,000 mg/dL (11.3 mmol/L)), it is reasonable to identify and address other    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ causes of hypertriglyceridemia, and if triglycerides are persistently elevated or increasing, to further reduce │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglycerides by implementation of a very low-fat diet, avoidance of refined carbohydrates and alcohol,         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ consumption of omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate therapy (S4.5.2-7, │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.5.2-9).|                                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Two categories of hypertriglyceridemia consist of moderate hypertriglyceridemia (fasting or nonfasting          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglycerides 175-499 mg/dL [2.0-5.6 mmol/L]) and severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [≥5.6 mmol/L]). In the former, excess triglycerides are carried in VLDL. In the latter, most patients have      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ elevated VLDL plus chylomicrons. VLDL are believed to be atherogenic, similar to LDL. There are many causes of  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ elevated VLDL, and it is reasonable to reduce their levels to reduce risk of ASCVD. With severe                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypertriglyceridemia, elevations of VLDL raise risk of ASCVD, but increases in chylomicrons impart risk of      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ acute pancreatitis. Therapies should address excesses in both lipoproteins.                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. In patients with moderate hypertriglyceridemia, it is reasonable to reduce both atherogenic VLDL and         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ associated risk factors by nonpharmacological means where possible. This can best be achieved by identification │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and treatment of the multiple underlying causes of elevated triglycerides (e.g., lifestyle causes, secondary    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ disorders, and triglyceride-raising drugs) (S4.5.2-1). Triglyceride-raising drugs include oral estrogens,       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ tamoxifen, raloxifene, retinoids,                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 73, N O . 2 4 , 2 0 1 9                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Grundy et al. e313                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E 25, 2 0 1 9 : e 2 8 5 - 3 5 0                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ As discussed in these guidelines (Section 4.2.) FH often goes undiagnosed. Young adults with primary elevations │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of LDL-C ≥ 190 mg/dl have a long-term ASCVD burden (S4.4.4.2-3), and statin therapy is recommended. In adults   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ with hypercholesterolemia, cascade screening often identifies other family members with elevated LDL-C (Section │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4.2.).                                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ However, even moderate hypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4).         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Secondary causes of elevated cholesterol—hypothyroidism (TSH), obstructive liver disease (liver panel), renal   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ disease and nephrosis (creatinine and urine analysis) as well as dietary and medication history—should be       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ addressed appropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ genetic forms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ to age 55 are shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ lifestyle change has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ A smaller group, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (LDL-C 160-189 mg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ present. Since there is increased probability of genetic FH in this LDL-C range, clinical judgment would        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ suggest that these high risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4.2.). Indeed, it has been shown that those with higher LDL-C can gain as much or more benefit from cholesterol │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduction as do those with lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ In young adults without phenotypically severe hypercholesterolemia, risk assessment should begin by estimation  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of lifetime risk (S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ starting at age 21 years (see Section 4.4.2.). This information can inform a focused risk discussion designed   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ to improve high-risk lifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S4.4.4.2-11, S4.4.4.2-12). When young adults with hypercholesterolemia or multiple risk factors are            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ identified, lifestyle intervention is indicated. To date, no long-term RCTs with cholesterol-lowering drugs     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ have been carried out in those 20 to 39 years age. However, a primary prevention RCT in those younger           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ individuals at low to moderate short-term risk, but at high lifetime risk has been proposed (S4.4.4.2-13).      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ One approach to identifying young adults who could benefit from statins or drug combination would be to detect  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ significant coronary atherosclerosis with coronary artery calcium (CAC) scores. Its use for this purpose has    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ been suggested (S4.4.4.2-14). But again, absence of RCT data precludes guideline recommendations at this time.  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.4.4.3. Children and Adolescents                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendations for Children and Adolescents                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Referenced studies that support recommendations are summarized in Online Data Supplements 18 to 21.             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|A|In children and adolescents with lipid disorders related to obesity, it is recommended to intensify        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ lifestyle therapy, including moderate caloric restriction and regular aerobic physical activity                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S4.4.4.3-1—S4.4.4.3-4).|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-NR|In children and adolescents with lipid abnormalities, lifestyle counseling is beneficial for lowering   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C (S4.4.4.3-1—S4.4.4.3-3,                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Grundy et al. e299                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E  2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ therapy. The same reasoning holds for any patient whose LDL-C level remains $70 mg/dL ($1.8 mmol/L) on          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ maximally tolerated statin therapy.                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.2. Severe Hypercholesterolemia (LDL-C ‡190 mg/dL [‡4.9 mmol/L])                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendations for Primary Severe Hypercholesterolemia (LDL-C $190 mg/dL [$4.9 mmol/L])                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Referenced studies that support recommendations are summarized in Online Data Supplements 9 and 10.             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-R|In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (‡4.9 mmol/L) maximally     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ tolerated statin therapy is recommended (S4.2-1—S4.2-7).|                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (‡4.9 mmol/L) who achieve │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ less than a 50% reduction in LDL-C while receiving maximally tolerated statin therapy and/or have an LDL-C      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ level of 100 mg/dL or higher (‡2.6 mmol/L) ezetimibe therapy is reasonable (S4.2-8—S4.2-10).|                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIb|B-R|In patients 20 to 75 years of age with a baseline LDL-C level 190 mg/dL or higher (‡4.9 mmol/L), who   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ achieve less than a 50% reduction in LDL-C levels and have fasting triglycerides 300 mg/dL or lower (£3.4       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mmol/L) while taking maximally tolerated statin and ezetimibe therapy, the addition of a bile acid sequestrant  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ may be considered (S4.2-11, S4.2-12).|                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIb|B-R|In patients 30 to 75 years of age with heterozygous FH and with an LDL-C level of 100 mg/dL or higher  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (‡2.6 mmol/L) while taking maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ may be considered (S4.2-9, S4.2-13—S4.2-15).|                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIb|C-LD|In patients 40 to 75 years of age with a baseline LDL-C level of 220 mg/dL or higher (‡5.7 mmol/L)    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and who achieve an on-treatment LDL-C level of 130 mg/dL or higher (‡3.4 mmol/L) while receiving maximally      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered (S4.2-13—S4.2-17).| │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Value Statement: Among patients with FH without evidence of clinical ASCVD taking maximally tolerated statin    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and ezetimibe therapy, PCSK9 inhibitors provide uncertain value at mid-2018 U.S. list prices.                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Patients with severe hypercholesterolemia have a high lifetime risk, and decisions about statins in these       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ patients do not require ASCVD risk scoring. These patients derive net ASCVD risk reduction benefit from         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ interventions that increase expression of LDL receptors. The strongest data have been derived from statin RCTs, │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ which have demonstrated greater risk reduction with statins than with moderate-intensity statin therapy.        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Ezetimibe plus a moderate-intensity statin is associated with greater LDL-C reduction than is statin            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ monotherapy in patients with heterozygous FH, and the combination reduces ASCVD risk more than                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ moderate-intensity statin monotherapy in patients who have had a recent ACS.                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Brottet et al.                                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # JACC Vol. 57, No. 8, 2011                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # ECVD Guideline: Full Text                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # February 22, 2011:e16 –94                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.2. Cessation of Tobacco Smoking                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.2.1. Recommendation for Cessation of Tobacco Smoking                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.3. Control of Hyperlipidemia                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.3.1. Recommendations for Control of Hyperlipidemia                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.4. Management of Diabetes Mellitus                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.4.1. Recommendations for Management of Diabetes Mellitus in Patients With Atherosclerosis of the            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Extracranial Carotid or Vertebral Arteries                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.5. Hyperhomocysteinemia                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.6. Obesity and the Metabolic Syndrome                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.7. Physical Inactivity                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.8. Antithrombotic Therapy                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.8.1. Recommendations for Antithrombotic Therapy in Patients With Extracranial Carotid Atherosclerotic       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Disease Not Undergoing Revascularization                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.8.2. Nonsteroidal Anti-Inflammatory Drugs                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7. Revascularization                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.1. Recommendations for Selection of Patients for Carotid Revascularization                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2. Carotid Endarterectomy                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.1. Randomized Trials of Carotid Endarterectomy                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.1.1. CAROTID ENDARTERECTOMY IN SYMPTOMATIC PATIENTS                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.1.2. CAROTID ENDARTERECTOMY IN ASYMPTOMATIC PATIENTS                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.2. Factors Affecting the Outcome of Carotid Endarterectomy                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.2.1. TECHNICAL CONSIDERATIONS                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.2.2. CASE SELECTION AND OPERATOR EXPERIENCE                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.2.3. DEMOGRAPHIC AND CLINICAL FACTORS                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.3. Risks Associated With Carotid Endarterectomy                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.4. Carotid Endarterectomy in Patients With Unfavorable Anatomy                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.5. Evolution in the Safety of Carotid Surgery                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.6. Evolution of Medical Therapy                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.7. Recommendations for Periprocedural Management of Patients Undergoing Carotid Endarterectomy            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3. Carotid Artery Stenting                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.1. Multicenter Registry Studies                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.2. Risks Associated With Carotid Artery Stenting                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.2.1. CARDIOVASCULAR COMPLICATIONS                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.2.2. NEUROLOGICAL COMPLICATIONS                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.3. Prevention of Cerebral Embolism in Patients Undergoing Catheter-Based Carotid Intervention             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.4. Intravascular Ultrasound Imaging in Conjunction With Catheter-Based Carotid Intervention               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.5. Management of Patients Undergoing Endovascular Carotid Artery Stenting                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4. Comparative Assessment of Carotid Endarterectomy and Stenting                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4.1. Nonrandomized Comparison of Carotid Endarterectomy With Carotid Artery Stenting                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4.2. Meta-Analyses Comparing Carotid Endarterectomy and Stenting                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4.3. Randomized Trials Comparing Carotid Endarterectomy and Carotid Artery Stenting                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4.3.1. HIGH-RISK PATIENTS                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4.3.2. CONVENTIONAL-RISK PATIENTS                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4.4. Selection of Carotid Endarterectomy or Carotid Artery Stenting for Individual Patients With Carotid    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Stenosis                                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.5. Durability of Carotid Revascularization                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.5.1. Recommendations for Management of Patients Experiencing Restenosis After Carotid Endarterectomy or     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Stenting                                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.5.2. Clinical Durability of Carotid Surgery and Carotid Stenting                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ #                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # e300 Grundy et al.                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral to a lipid specialist  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ may be indicated.                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Patients with primary severe hypercholesterolemia (LDL-C levels ≥190 mg/dL [≥4.9 mmol/L]) have a high-risk   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of ASCVD (S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ been no randomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ≥190 mg/dL (≥4.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean baseline   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular death in  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ those receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis of 2,560  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ exclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial long-term         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ follow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin therapy      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with phenotypic or     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ genetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce ASCVD risk in   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ both primary- and secondary-prevention trials and because high-intensity statins provide greater ASCVD risk     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy should be     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ administered to patients with primary severe hypercholesterolemia.                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. A large placebo-controlled RCT examined the effect of simvastatin 80 mg daily, with or without ezetimibe 10  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mg daily, on carotid intima-media thickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ greater in the combined-therapy group, but there was no difference in carotid intima-media thickness between    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ the 2 groups. The study was not powered to examine the risk of ASCVD events (S4.2-10). However, a very large    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ placebo-controlled RCT examining ASCVD outcomes in post-ACS patients, performed over a period of 7 years,       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ showed that the addition of ezetimibe 10 mg to simvastatin 40 mg daily resulted in greater ASCVD risk reduction │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ than that produced by statin monotherapy (S4.2-8). Secondary-prevention patients with certain ASCVD risk        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ indicators exhibit greater ASCVD risk reduction from ezetimibe therapy than do patients without these           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ characteristics (S4.2-20). Patients with severe hypercholesterolemia who are adherent to statins, achieve &lt;50%  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduction in LDL-C levels with maximally tolerated statin therapy, and have an LDL-C level ≥100 mg/dL (≥2.6     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mmol/L) are likely to derive additional ASCVD risk reduction from ezetimibe add-on therapy through additional   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C lowering (S4.2-9).                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 3. When administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ with or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12). │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ However, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ used in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation.        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Nonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ cholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4. PCSK9 inhibitors are promising drugs for treatment of FH                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 73, N O . 24, 2019                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Grundy et al. e315                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E 25, 2019: e 285 - 350                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # T A B L E 9 Normal and Abnormal Lipid Values in Childhood*                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ | |Acceptable, mg/dL|Borderline, mg/dL|Abnormal, mg/dL|                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|---|                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |TC|&amp;lt;170 (&amp;lt;4.3 mmol/L)|170-199 (4.3-5.1 mmol/L)|$200 ($5.1 mmol/L)|                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Triglycerides (0-9 y)|&amp;lt;75 (&amp;lt;0.8 mmol/L)|75-99 (0.8-1.1 mmol/L)|$100 ($1.1 mmol/L)|                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Triglycerides (10-19 y)|&amp;lt;90 (&amp;lt;1.0 mmol/L)|90-129 (1.0-1.5 mmol/L)|$130 ($1.4 mmol/L)|                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |HDL-C|&amp;gt;45 (&amp;gt;1.2 mmol/L)|40-45 (1.0-1.2 mmol/L)|&amp;lt;40 (&amp;lt;1.0 mmol/L)|                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |LDL-C|&amp;lt;110 (&amp;lt;2.8 mmol/L)|110-129 (2.8-3.3 mmol/L)|$130 ($3.4 mmol/L)|                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Non–HDL-C|&amp;lt;120 (&amp;lt;3.1 mmol/L)|120-144 (3.1-3.7 mmol/L)|$145 ($3.7 mmol/L)|                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Values given are in mg/dL. To convert to SI units, divide the results for TC, LDL-C, HDL-C, and non–HDL-C by    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 38.6; for triglycerides, divide by 88.6.                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ *Values for plasma lipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Children. Non–HDL-C values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ for LDL-C.                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ †The cutpoints for high and borderline high represent approximately the 95th and 75th percentiles,              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ respectively. Low cutpoints for HDL-C represent approximately the 10th percentile.                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP,         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ National Cholesterol Education Program; SI, Système international d’unités (International System of Units); and │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ TC, total cholesterol.                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Hypercholesterolemia show reasonable LDL-C lowering with no significant adverse effects (S4.4.4.3-13).          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Nonsystemic bile acid sequestrants can be useful for LDL-C lowering, but tolerability is an issue               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S4.4.4.3-13—S4.4.4.3-16).                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4. Lipid testing during childhood can identify the severe hypercholesterolemia phenotype (S4.4.4.3-35). Severe  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypercholesterolemia, which includes FH, can be identified in children and adolescents with an LDL-C level $190 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mg/dL ($4.9 mmol/L). Moreover, children and adolescents with LDL-C $160 mg/dL ($4.1 mmol/L) and a family        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ history of early atherosclerosis or similarly elevated cholesterol in 1 parent likely are those with FH and     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ related genetic disorders associated with accelerated ASCVD (S4.4.4.3-17—S4.4.4.3-21).                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Subclinical atherosclerosis data suggest divergence between affected and unaffected children and adolescents    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ beginning at age 10 years (S4.4.4.3-28), which supports screening by this age, although this topic is still     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ considered controversial (S4.4.4.3-36). Screening is advised beginning at age 2 years if a family history is    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ suggestive of either early CVD or significant primary hypercholesterolemia. Identification of a child with      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ severe hypercholesterolemia should prompt screening of extended family members (e.g., reverse-cascade           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ screening), according to studies outside the United States demonstrating efficacy of this approach              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S4.4.4.3-37). Screening for severe                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ children and adolescents with lipid disorders related to obesity, it is recommended to intensify lifestyle      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ therapy, including moderate caloric restriction and regular aerobic physical activity (S4.4.4.3-1—S4.4.4.3-4).| │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-NR|In children and adolescents with lipid abnormalities, lifestyle counseling is beneficial for lowering   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C (S4.4.4.3-1—S4.4.4.3-3, S4.4.4.3-5—S4.4.4.3-12).|                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In children and adolescents 10 years of age or older with an LDL-C level persistently 190 mg/dL or     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ higher (≥4.9 mmol/L) or 160 mg/dL or higher (≥4.1 mmol/L) with a clinical presentation consistent with FH (see  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Section 4.2.) and who do not respond adequately with 3 to 6 months of lifestyle therapy, it is reasonable to    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ initiate statin therapy (S4.4.4.3-13—S4.4.4.3-16).|                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-NR|In children and adolescents with a family history of either early CVD* or significant                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypercholesterolemia,† it is reasonable to measure a fasting or nonfasting lipoprotein profile as early as age  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2 years to detect FH or rare forms of hypercholesterolemia (S4.4.4.3-17—S4.4.4.3-21).|                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-NR|In children and adolescents found to have moderate or severe hypercholesterolemia, it is reasonable   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ to carry out reverse-cascade screening of family members, which includes cholesterol testing for first-,        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ second-, and when possible, third-degree biological relatives, for detection of familial forms of               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypercholesterolemia (S4.4.4.3-22—S4.4.4.3-24).|                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of severe hypertriglyceridemic pregnancy is also beyond the scope of the present guideline and requires         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ consultation with an experienced lipid specialist.                                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.5.4. Adults With CKD                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendations for Adults With CKD                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Referenced studies that support recommendations are summarized in Online Data Supplements 36 to 38.             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL (1.7 to 4.8 mmol/L) who are at 10-year      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ASCVD risk of 7.5% or higher, CKD not treated with dialysis or kidney transplantation is a risk-enhancing       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ factor and initiation of a moderate-intensity statin or moderate-intensity statins combined with ezetimibe can  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ be useful (S4.5.4-1, S4.5.4-2).|                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIb|C-LD|In adults with advanced kidney disease that requires dialysis treatment who are currently on          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-lowering therapy with a statin, it may be reasonable to continue the statin (S4.5.4-2).|                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |III: No Benefit|B-R|In adults with advanced kidney disease who require dialysis treatment, initiation of a     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ statin is not recommended (S4.5.4-3, S4.5.4-4).|                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2.2. Lipid Measurement                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Modest differences in LDL-C levels associated with the postprandial state, use of a nonfasting sample is        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ effective to document baseline lipid levels before initiation of statin therapy in individuals with clinical    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ASCVD (S2.2-1—S2.2-6). In adults with a family history of premature ASCVD or genetic hyperlipidemia, a fasting  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ lipid profile is reasonable for initial evaluation.                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Given relatively modest differences in LDL-C levels between fasting and non-fasting samples, the latter is   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ generally adequate to document baseline lipid levels prior to initiation of statin therapy (S2.2-1—S2.2-6).     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. The unreliability of the Friedewald-calculated LDL-C levels rises at lower levels of LDL-C, particularly &lt;70 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mg/dL (&lt;1.8 mmol/L). If accurate measurements of LDL-C levels are needed at very low LDL-C, calculation         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ adjustments can be used (S2.2-7—S2.2-9). Measurement of apoB may be useful in determining whether               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypertriglyceridemia is an atherogenic condition (S2.2-12, S2.2-13).                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 3. In adults with a family history of premature ASCVD or genetic hyperlipidemia, a fasting lipid profile is     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reasonable for initial evaluation to aid in the understanding and identification of familial lipid disorders    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S2.2-12, S2.2-13).                                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2.3. Measurements of Apolipoprotein B and Lipoprotein (a)                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Two lipoprotein entities related to LDL-C are apoB and lipoprotein (a) [Lp(a)]. Because apoB is the major       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ apolipoprotein embedded in LDL and VLDL, several investigators identify strength of association between apoB    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and ASCVD (S2.3-1). Others report a high correlation between apoB and non–HDL-C (S2.3-2). Under certain         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ circumstances, particularly in patients with hypertriglyceridemia, the measurement of apoB may have advantages  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S2.3-3). Nevertheless, apoB measurement carries extra expense, and its measurement in some laboratories may    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ not be reliable (S2.3-4). A relative indication for its measurement would be triglyceride $200 mg/dL. A level   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ &gt;130 mg/dL corresponds to an LDL-C level $160 mg/dL and constitutes a risk-enhancing factor. A persistent       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ elevation of apoB can be considered a risk-enhancing factor. Separately, Lp(a) is a modified form of LDL that   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ appears to possess atherogenic potential (S2.3-5). Relative indications for its measurement are family history  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of premature ASCVD or personal history of ASCVD not explained by major risk factors. Lp(a) increases ASCVD risk │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ especially at higher levels. Thus, if a decision is made to measure Lp(a), an Lp(a) $50 mg/dL or $125 nmol/L,   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Lp(a) may be considered a risk-enhancing factor (S2.3-6). Current evidence shows that it should be considered   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ in women only in the presence of hypercholesterolemia and with the understanding that the improvement in risk   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ prediction in adult women in a large clinical trial was minimal (S2.3-7). In the present document, an elevation │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of Lp(a) is considered to be a risk-enhancing factor (S2.3-6). This is especially in those with higher Lp(a)    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ values and, if used in women, only in the presence of hypercholesterolemia (S2.3-7).                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2.4. Monitoring Response of LDL-C to Statin Therapy                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ In large RCTs of cholesterol-lowering therapy, LDL-C lowering has been consistently shown to reduce the risk of │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ASCVD. One large meta-analysis (S2.4-1) of statin clinical trials showed a progressive reduction in risk of     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ major ASCVD events with lower on-treatment LDL-C levels. In another larger meta-analysis (S2.4-2) of 14 statin  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ trials, it was observed that a 38.7-mg/dL (1-mmol/L) reduction of LDL-C levels is accompanied by a 21%          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduction in ASCVD risk. In clinical practice, however, absolute responses in LDL-C to statin therapy depend on │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ baseline                                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output: than in former smokers, and there was a significant relationship between the \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mseverity of carotid stenosis and pack-years of exposure to tobacco (239). The RRs of finding 60% carotid \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstenosis were 1.5 and 3.9 among cigarette smokers with cerebral ischemia in the NOMASS and the BCID (Berlin \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCerebral Ischemia Databank) studies, respectively (258).\u001b[0m\u001b[3;34m                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.3. Control of Hyperlipidemia\u001b[0m\u001b[3;34m                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.3.1. Recommendations for Control of Hyperlipidemia\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCLASS I\u001b[0m\u001b[3;34m                                                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Treatment with a statin medication is recommended for all patients with extracranial carotid or vertebral \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34matherosclerosis to reduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mEvidence: B)\u001b[0m\u001b[3;34m                                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCLASS IIa\u001b[0m\u001b[3;34m                                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or vertebral \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34matherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70 mg/dL (259). \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(Level of Evidence: B)\u001b[0m\u001b[3;34m                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. If treatment with a statin (including trials of higher-dose statins and higher-potency statins) does not \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34machieve the goal selected for a patient, intensifying LDL-lowering drug therapy with an additional drug from \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mamong those with evidence of improving outcomes (i.e., bile acid sequestrants or niacin) can be effective \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(261–264). (Level of Evidence: B)\u001b[0m\u001b[3;34m                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m3. For patients who do not tolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreasonable (261,263,265). (Level of Evidence: B)\u001b[0m\u001b[3;34m                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe relationship between cholesterol and ischemic stroke is not as evident as that between cholesterol and MI, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand findings from population-based studies are inconsistent. In the MR FIT (Multiple Risk Factor Intervention \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTrial), comprising more than 350,000 men, the RR of death increased progressively with serum cholesterol, \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mexceeding 2.5 in those with the highest levels (266). An analysis of 45 prospective observational cohorts \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34minvolving approximately 450,000 individuals, however, found no association of hypercholesterolemia with stroke \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(267). In the ARIC study, the relationships between lipid values and incident ischemic.\u001b[0m\u001b[3;34m                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# e318\u001b[0m\u001b[3;34m                                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Grundy et al.\u001b[0m\u001b[3;34m                                                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E  2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.5.2. Hypertriglyceridemia\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendations for Hypertriglyceridemia\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferenced studies that support recommendations are summarized in Online Data Supplements 31 and 32.\u001b[0m\u001b[3;34m           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-NR|In adults 20 years of age or older with moderate hypertriglyceridemia (fasting or nonfasting \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglycerides 175 to 499 mg/dL [2.0 to 5.6 mmol/L]), clinicians should address and treat lifestyle factors \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(obesity and metabolic syndrome), secondary factors (diabetes mellitus, chronic liver or kidney disease and/or \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mnephrotic syndrome, hypothyroidism), and medications that increase triglycerides (S4.5.2-1).|\u001b[0m\u001b[3;34m                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In adults 40 to 75 years of age with moderate or severe hypertriglyceridemia and ASCVD risk of 7.5% or\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhigher, it is reasonable to reevaluate ASCVD risk after lifestyle and secondary factors are addressed and to \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mconsider a persistently elevated triglyceride level as a factor favoring initiation or intensification of \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstatin therapy (see Section 4.4.2.) (S4.5.2-2—S4.5.2-6).|\u001b[0m\u001b[3;34m                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In adults 40 to 75 years of age with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[≥5.6 mmol/L]) and ASCVD risk of 7.5% or higher, it is reasonable to address reversible causes of high \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglyceride and to initiate statin therapy (S4.5.2-3—S4.5.2-5, S4.5.2-7, S4.5.2-8).|\u001b[0m\u001b[3;34m                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-NR|In adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L]), and \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mespecially fasting triglycerides ≥1,000 mg/dL (11.3 mmol/L)), it is reasonable to identify and address other \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcauses of hypertriglyceridemia, and if triglycerides are persistently elevated or increasing, to further reduce\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglycerides by implementation of a very low-fat diet, avoidance of refined carbohydrates and alcohol, \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mconsumption of omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate therapy (S4.5.2-7,\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.5.2-9).|\u001b[0m\u001b[3;34m                                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Synopsis\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTwo categories of hypertriglyceridemia consist of moderate hypertriglyceridemia (fasting or nonfasting \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglycerides 175-499 mg/dL [2.0-5.6 mmol/L]) and severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[≥5.6 mmol/L]). In the former, excess triglycerides are carried in VLDL. In the latter, most patients have \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34melevated VLDL plus chylomicrons. VLDL are believed to be atherogenic, similar to LDL. There are many causes of \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34melevated VLDL, and it is reasonable to reduce their levels to reduce risk of ASCVD. With severe \u001b[0m\u001b[3;34m               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypertriglyceridemia, elevations of VLDL raise risk of ASCVD, but increases in chylomicrons impart risk of \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34macute pancreatitis. Therapies should address excesses in both lipoproteins.\u001b[0m\u001b[3;34m                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation-Specific Supportive Text\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. In patients with moderate hypertriglyceridemia, it is reasonable to reduce both atherogenic VLDL and \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34massociated risk factors by nonpharmacological means where possible. This can best be achieved by identification\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand treatment of the multiple underlying causes of elevated triglycerides (e.g., lifestyle causes, secondary \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdisorders, and triglyceride-raising drugs) (S4.5.2-1). Triglyceride-raising drugs include oral estrogens, \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtamoxifen, raloxifene, retinoids,\u001b[0m\u001b[3;34m                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 73, N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Grundy et al. e313\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E 25, 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[3;34m                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAs discussed in these guidelines (Section 4.2.) FH often goes undiagnosed. Young adults with primary elevations\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof LDL-C ≥ 190 mg/dl have a long-term ASCVD burden (S4.4.4.2-3), and statin therapy is recommended. In adults \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwith hypercholesterolemia, cascade screening often identifies other family members with elevated LDL-C (Section\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4.2.).\u001b[0m\u001b[3;34m                                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHowever, even moderate hypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4). \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSecondary causes of elevated cholesterol—hypothyroidism (TSH), obstructive liver disease (liver panel), renal \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdisease and nephrosis (creatinine and urine analysis) as well as dietary and medication history—should be \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34maddressed appropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgenetic forms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mto age 55 are shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlifestyle change has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.\u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mA smaller group, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(LDL-C 160-189 mg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpresent. Since there is increased probability of genetic FH in this LDL-C range, clinical judgment would \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msuggest that these high risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4.2.). Indeed, it has been shown that those with higher LDL-C can gain as much or more benefit from cholesterol\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduction as do those with lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).\u001b[0m\u001b[3;34m               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mIn young adults without phenotypically severe hypercholesterolemia, risk assessment should begin by estimation \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof lifetime risk (S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstarting at age 21 years (see Section 4.4.2.). This information can inform a focused risk discussion designed \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mto improve high-risk lifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S4.4.4.2-11, S4.4.4.2-12). When young adults with hypercholesterolemia or multiple risk factors are \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34midentified, lifestyle intervention is indicated. To date, no long-term RCTs with cholesterol-lowering drugs \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhave been carried out in those 20 to 39 years age. However, a primary prevention RCT in those younger \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mindividuals at low to moderate short-term risk, but at high lifetime risk has been proposed (S4.4.4.2-13).\u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mOne approach to identifying young adults who could benefit from statins or drug combination would be to detect \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msignificant coronary atherosclerosis with coronary artery calcium (CAC) scores. Its use for this purpose has \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbeen suggested (S4.4.4.2-14). But again, absence of RCT data precludes guideline recommendations at this time.\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.4.4.3. Children and Adolescents\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendations for Children and Adolescents\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferenced studies that support recommendations are summarized in Online Data Supplements 18 to 21.\u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|A|In children and adolescents with lipid disorders related to obesity, it is recommended to intensify \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlifestyle therapy, including moderate caloric restriction and regular aerobic physical activity \u001b[0m\u001b[3;34m               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S4.4.4.3-1—S4.4.4.3-4).|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-NR|In children and adolescents with lipid abnormalities, lifestyle counseling is beneficial for lowering \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C (S4.4.4.3-1—S4.4.4.3-3,\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Grundy et al. e299\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E  2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtherapy. The same reasoning holds for any patient whose LDL-C level remains $70 mg/dL ($1.8 mmol/L) on \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmaximally tolerated statin therapy.\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.2. Severe Hypercholesterolemia (LDL-C ‡190 mg/dL [‡4.9 mmol/L])\u001b[0m\u001b[3;34m                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendations for Primary Severe Hypercholesterolemia (LDL-C $190 mg/dL [$4.9 mmol/L])\u001b[0m\u001b[3;34m                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferenced studies that support recommendations are summarized in Online Data Supplements 9 and 10.\u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-R|In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (‡4.9 mmol/L) maximally \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtolerated statin therapy is recommended (S4.2-1—S4.2-7).|\u001b[0m\u001b[3;34m                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In patients 20 to 75 years of age with an LDL-C level of 190 mg/dL or higher (‡4.9 mmol/L) who achieve\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mless than a 50% reduction in LDL-C while receiving maximally tolerated statin therapy and/or have an LDL-C \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlevel of 100 mg/dL or higher (‡2.6 mmol/L) ezetimibe therapy is reasonable (S4.2-8—S4.2-10).|\u001b[0m\u001b[3;34m                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIb|B-R|In patients 20 to 75 years of age with a baseline LDL-C level 190 mg/dL or higher (‡4.9 mmol/L), who \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34machieve less than a 50% reduction in LDL-C levels and have fasting triglycerides 300 mg/dL or lower (£3.4 \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmmol/L) while taking maximally tolerated statin and ezetimibe therapy, the addition of a bile acid sequestrant \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmay be considered (S4.2-11, S4.2-12).|\u001b[0m\u001b[3;34m                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIb|B-R|In patients 30 to 75 years of age with heterozygous FH and with an LDL-C level of 100 mg/dL or higher \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(‡2.6 mmol/L) while taking maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmay be considered (S4.2-9, S4.2-13—S4.2-15).|\u001b[0m\u001b[3;34m                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIb|C-LD|In patients 40 to 75 years of age with a baseline LDL-C level of 220 mg/dL or higher (‡5.7 mmol/L) \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand who achieve an on-treatment LDL-C level of 130 mg/dL or higher (‡3.4 mmol/L) while receiving maximally \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered (S4.2-13—S4.2-17).|\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mValue Statement: Among patients with FH without evidence of clinical ASCVD taking maximally tolerated statin \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand ezetimibe therapy, PCSK9 inhibitors provide uncertain value at mid-2018 U.S. list prices.\u001b[0m\u001b[3;34m                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Synopsis\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mPatients with severe hypercholesterolemia have a high lifetime risk, and decisions about statins in these \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpatients do not require ASCVD risk scoring. These patients derive net ASCVD risk reduction benefit from \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34minterventions that increase expression of LDL receptors. The strongest data have been derived from statin RCTs,\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwhich have demonstrated greater risk reduction with statins than with moderate-intensity statin therapy. \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mEzetimibe plus a moderate-intensity statin is associated with greater LDL-C reduction than is statin \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmonotherapy in patients with heterozygous FH, and the combination reduces ASCVD risk more than \u001b[0m\u001b[3;34m                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmoderate-intensity statin monotherapy in patients who have had a recent ACS.\u001b[0m\u001b[3;34m                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Brottet et al.\u001b[0m\u001b[3;34m                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# JACC Vol. 57, No. 8, 2011\u001b[0m\u001b[3;34m                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# ECVD Guideline: Full Text\u001b[0m\u001b[3;34m                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# February 22, 2011:e16 –94\u001b[0m\u001b[3;34m                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.2. Cessation of Tobacco Smoking\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.2.1. Recommendation for Cessation of Tobacco Smoking\u001b[0m\u001b[3;34m                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.3. Control of Hyperlipidemia\u001b[0m\u001b[3;34m                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.3.1. Recommendations for Control of Hyperlipidemia\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.4. Management of Diabetes Mellitus\u001b[0m\u001b[3;34m                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.4.1. Recommendations for Management of Diabetes Mellitus in Patients With Atherosclerosis of the \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mExtracranial Carotid or Vertebral Arteries\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.5. Hyperhomocysteinemia\u001b[0m\u001b[3;34m                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.6. Obesity and the Metabolic Syndrome\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.7. Physical Inactivity\u001b[0m\u001b[3;34m                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.8. Antithrombotic Therapy\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.8.1. Recommendations for Antithrombotic Therapy in Patients With Extracranial Carotid Atherosclerotic \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mDisease Not Undergoing Revascularization\u001b[0m\u001b[3;34m                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.8.2. Nonsteroidal Anti-Inflammatory Drugs\u001b[0m\u001b[3;34m                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7. Revascularization\u001b[0m\u001b[3;34m                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.1. Recommendations for Selection of Patients for Carotid Revascularization\u001b[0m\u001b[3;34m                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2. Carotid Endarterectomy\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.1. Randomized Trials of Carotid Endarterectomy\u001b[0m\u001b[3;34m                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.1.1. CAROTID ENDARTERECTOMY IN SYMPTOMATIC PATIENTS\u001b[0m\u001b[3;34m                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.1.2. CAROTID ENDARTERECTOMY IN ASYMPTOMATIC PATIENTS\u001b[0m\u001b[3;34m                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.2. Factors Affecting the Outcome of Carotid Endarterectomy\u001b[0m\u001b[3;34m                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.2.1. TECHNICAL CONSIDERATIONS\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.2.2. CASE SELECTION AND OPERATOR EXPERIENCE\u001b[0m\u001b[3;34m                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.2.3. DEMOGRAPHIC AND CLINICAL FACTORS\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.3. Risks Associated With Carotid Endarterectomy\u001b[0m\u001b[3;34m                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.4. Carotid Endarterectomy in Patients With Unfavorable Anatomy\u001b[0m\u001b[3;34m                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.5. Evolution in the Safety of Carotid Surgery\u001b[0m\u001b[3;34m                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.6. Evolution of Medical Therapy\u001b[0m\u001b[3;34m                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.7. Recommendations for Periprocedural Management of Patients Undergoing Carotid Endarterectomy\u001b[0m\u001b[3;34m           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3. Carotid Artery Stenting\u001b[0m\u001b[3;34m                                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.1. Multicenter Registry Studies\u001b[0m\u001b[3;34m                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.2. Risks Associated With Carotid Artery Stenting\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.2.1. CARDIOVASCULAR COMPLICATIONS\u001b[0m\u001b[3;34m                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.2.2. NEUROLOGICAL COMPLICATIONS\u001b[0m\u001b[3;34m                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.3. Prevention of Cerebral Embolism in Patients Undergoing Catheter-Based Carotid Intervention\u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.4. Intravascular Ultrasound Imaging in Conjunction With Catheter-Based Carotid Intervention\u001b[0m\u001b[3;34m              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.5. Management of Patients Undergoing Endovascular Carotid Artery Stenting\u001b[0m\u001b[3;34m                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4. Comparative Assessment of Carotid Endarterectomy and Stenting\u001b[0m\u001b[3;34m                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4.1. Nonrandomized Comparison of Carotid Endarterectomy With Carotid Artery Stenting\u001b[0m\u001b[3;34m                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4.2. Meta-Analyses Comparing Carotid Endarterectomy and Stenting\u001b[0m\u001b[3;34m                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4.3. Randomized Trials Comparing Carotid Endarterectomy and Carotid Artery Stenting\u001b[0m\u001b[3;34m                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4.3.1. HIGH-RISK PATIENTS\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4.3.2. CONVENTIONAL-RISK PATIENTS\u001b[0m\u001b[3;34m                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4.4. Selection of Carotid Endarterectomy or Carotid Artery Stenting for Individual Patients With Carotid \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mStenosis\u001b[0m\u001b[3;34m                                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.5. Durability of Carotid Revascularization\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.5.1. Recommendations for Management of Patients Experiencing Restenosis After Carotid Endarterectomy or \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mStenting\u001b[0m\u001b[3;34m                                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.5.2. Clinical Durability of Carotid Surgery and Carotid Stenting\u001b[0m\u001b[3;34m                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m#\u001b[0m\u001b[3;34m                                                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# e300 Grundy et al.\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral to a lipid specialist \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmay be indicated.\u001b[0m\u001b[3;34m                                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation-Specific Supportive Text\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Patients with primary severe hypercholesterolemia (LDL-C levels ≥190 mg/dL [≥4.9 mmol/L]) have a high-risk \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof ASCVD (S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbeen no randomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m≥190 mg/dL (≥4.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean baseline \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular death in \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthose receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis of 2,560 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mexclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial long-term \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfollow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin therapy \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with phenotypic or \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgenetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce ASCVD risk in \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mboth primary- and secondary-prevention trials and because high-intensity statins provide greater ASCVD risk \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy should be \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34madministered to patients with primary severe hypercholesterolemia.\u001b[0m\u001b[3;34m                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. A large placebo-controlled RCT examined the effect of simvastatin 80 mg daily, with or without ezetimibe 10 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmg daily, on carotid intima-media thickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgreater in the combined-therapy group, but there was no difference in carotid intima-media thickness between \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthe 2 groups. The study was not powered to examine the risk of ASCVD events (S4.2-10). However, a very large \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mplacebo-controlled RCT examining ASCVD outcomes in post-ACS patients, performed over a period of 7 years, \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mshowed that the addition of ezetimibe 10 mg to simvastatin 40 mg daily resulted in greater ASCVD risk reduction\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthan that produced by statin monotherapy (S4.2-8). Secondary-prevention patients with certain ASCVD risk \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mindicators exhibit greater ASCVD risk reduction from ezetimibe therapy than do patients without these \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcharacteristics (S4.2-20). Patients with severe hypercholesterolemia who are adherent to statins, achieve <50% \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduction in LDL-C levels with maximally tolerated statin therapy, and have an LDL-C level ≥100 mg/dL (≥2.6 \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmmol/L) are likely to derive additional ASCVD risk reduction from ezetimibe add-on therapy through additional \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C lowering (S4.2-9).\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m3. When administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwith or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12).\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHowever, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mused in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation. \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.\u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4. PCSK9 inhibitors are promising drugs for treatment of FH\u001b[0m\u001b[3;34m                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 73, N O . 24, 2019\u001b[0m\u001b[3;34m                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Grundy et al. e315\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E 25, 2019: e 285 - 350\u001b[0m\u001b[3;34m                                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# T A B L E 9 Normal and Abnormal Lipid Values in Childhood*\u001b[0m\u001b[3;34m                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m| |Acceptable, mg/dL|Borderline, mg/dL|Abnormal, mg/dL|\u001b[0m\u001b[3;34m                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|---|\u001b[0m\u001b[3;34m                                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|TC|&lt;170 (&lt;4.3 mmol/L)|170-199 (4.3-5.1 mmol/L)|$200 ($5.1 mmol/L)|\u001b[0m\u001b[3;34m                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Triglycerides (0-9 y)|&lt;75 (&lt;0.8 mmol/L)|75-99 (0.8-1.1 mmol/L)|$100 ($1.1 mmol/L)|\u001b[0m\u001b[3;34m                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Triglycerides (10-19 y)|&lt;90 (&lt;1.0 mmol/L)|90-129 (1.0-1.5 mmol/L)|$130 ($1.4 mmol/L)|\u001b[0m\u001b[3;34m                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|HDL-C|&gt;45 (&gt;1.2 mmol/L)|40-45 (1.0-1.2 mmol/L)|&lt;40 (&lt;1.0 mmol/L)|\u001b[0m\u001b[3;34m                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|LDL-C|&lt;110 (&lt;2.8 mmol/L)|110-129 (2.8-3.3 mmol/L)|$130 ($3.4 mmol/L)|\u001b[0m\u001b[3;34m                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Non–HDL-C|&lt;120 (&lt;3.1 mmol/L)|120-144 (3.1-3.7 mmol/L)|$145 ($3.7 mmol/L)|\u001b[0m\u001b[3;34m                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mValues given are in mg/dL. To convert to SI units, divide the results for TC, LDL-C, HDL-C, and non–HDL-C by \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m38.6; for triglycerides, divide by 88.6.\u001b[0m\u001b[3;34m                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m*Values for plasma lipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mChildren. Non–HDL-C values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfor LDL-C.\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m†The cutpoints for high and borderline high represent approximately the 95th and 75th percentiles, \u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mrespectively. Low cutpoints for HDL-C represent approximately the 10th percentile.\u001b[0m\u001b[3;34m                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP, \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNational Cholesterol Education Program; SI, Système international d’unités (International System of Units); and\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTC, total cholesterol.\u001b[0m\u001b[3;34m                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHypercholesterolemia show reasonable LDL-C lowering with no significant adverse effects (S4.4.4.3-13). \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNonsystemic bile acid sequestrants can be useful for LDL-C lowering, but tolerability is an issue \u001b[0m\u001b[3;34m             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S4.4.4.3-13—S4.4.4.3-16).\u001b[0m\u001b[3;34m                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4. Lipid testing during childhood can identify the severe hypercholesterolemia phenotype (S4.4.4.3-35). Severe \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypercholesterolemia, which includes FH, can be identified in children and adolescents with an LDL-C level $190\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmg/dL ($4.9 mmol/L). Moreover, children and adolescents with LDL-C $160 mg/dL ($4.1 mmol/L) and a family \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhistory of early atherosclerosis or similarly elevated cholesterol in 1 parent likely are those with FH and \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mrelated genetic disorders associated with accelerated ASCVD (S4.4.4.3-17—S4.4.4.3-21).\u001b[0m\u001b[3;34m                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSubclinical atherosclerosis data suggest divergence between affected and unaffected children and adolescents \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbeginning at age 10 years (S4.4.4.3-28), which supports screening by this age, although this topic is still \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mconsidered controversial (S4.4.4.3-36). Screening is advised beginning at age 2 years if a family history is \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msuggestive of either early CVD or significant primary hypercholesterolemia. Identification of a child with \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msevere hypercholesterolemia should prompt screening of extended family members (e.g., reverse-cascade \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mscreening), according to studies outside the United States demonstrating efficacy of this approach \u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S4.4.4.3-37). Screening for severe\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mchildren and adolescents with lipid disorders related to obesity, it is recommended to intensify lifestyle \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtherapy, including moderate caloric restriction and regular aerobic physical activity (S4.4.4.3-1—S4.4.4.3-4).|\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-NR|In children and adolescents with lipid abnormalities, lifestyle counseling is beneficial for lowering \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C (S4.4.4.3-1—S4.4.4.3-3, S4.4.4.3-5—S4.4.4.3-12).|\u001b[0m\u001b[3;34m                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In children and adolescents 10 years of age or older with an LDL-C level persistently 190 mg/dL or \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhigher (≥4.9 mmol/L) or 160 mg/dL or higher (≥4.1 mmol/L) with a clinical presentation consistent with FH (see \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSection 4.2.) and who do not respond adequately with 3 to 6 months of lifestyle therapy, it is reasonable to \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34minitiate statin therapy (S4.4.4.3-13—S4.4.4.3-16).|\u001b[0m\u001b[3;34m                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-NR|In children and adolescents with a family history of either early CVD* or significant \u001b[0m\u001b[3;34m               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypercholesterolemia,† it is reasonable to measure a fasting or nonfasting lipoprotein profile as early as age \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2 years to detect FH or rare forms of hypercholesterolemia (S4.4.4.3-17—S4.4.4.3-21).|\u001b[0m\u001b[3;34m                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-NR|In children and adolescents found to have moderate or severe hypercholesterolemia, it is reasonable \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mto carry out reverse-cascade screening of family members, which includes cholesterol testing for first-, \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msecond-, and when possible, third-degree biological relatives, for detection of familial forms of \u001b[0m\u001b[3;34m             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypercholesterolemia (S4.4.4.3-22—S4.4.4.3-24).|\u001b[0m\u001b[3;34m                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof severe hypertriglyceridemic pregnancy is also beyond the scope of the present guideline and requires \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mconsultation with an experienced lipid specialist.\u001b[0m\u001b[3;34m                                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.5.4. Adults With CKD\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendations for Adults With CKD\u001b[0m\u001b[3;34m                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferenced studies that support recommendations are summarized in Online Data Supplements 36 to 38.\u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL (1.7 to 4.8 mmol/L) who are at 10-year \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mASCVD risk of 7.5% or higher, CKD not treated with dialysis or kidney transplantation is a risk-enhancing \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfactor and initiation of a moderate-intensity statin or moderate-intensity statins combined with ezetimibe can \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbe useful (S4.5.4-1, S4.5.4-2).|\u001b[0m\u001b[3;34m                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIb|C-LD|In adults with advanced kidney disease that requires dialysis treatment who are currently on \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-lowering therapy with a statin, it may be reasonable to continue the statin (S4.5.4-2).|\u001b[0m\u001b[3;34m                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|III: No Benefit|B-R|In adults with advanced kidney disease who require dialysis treatment, initiation of a \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstatin is not recommended (S4.5.4-3, S4.5.4-4).|\u001b[0m\u001b[3;34m                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2.2. Lipid Measurement\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mModest differences in LDL-C levels associated with the postprandial state, use of a nonfasting sample is \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34meffective to document baseline lipid levels before initiation of statin therapy in individuals with clinical \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mASCVD (S2.2-1—S2.2-6). In adults with a family history of premature ASCVD or genetic hyperlipidemia, a fasting \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlipid profile is reasonable for initial evaluation.\u001b[0m\u001b[3;34m                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Given relatively modest differences in LDL-C levels between fasting and non-fasting samples, the latter is \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgenerally adequate to document baseline lipid levels prior to initiation of statin therapy (S2.2-1—S2.2-6).\u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. The unreliability of the Friedewald-calculated LDL-C levels rises at lower levels of LDL-C, particularly <70\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmg/dL (<1.8 mmol/L). If accurate measurements of LDL-C levels are needed at very low LDL-C, calculation \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34madjustments can be used (S2.2-7—S2.2-9). Measurement of apoB may be useful in determining whether \u001b[0m\u001b[3;34m             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypertriglyceridemia is an atherogenic condition (S2.2-12, S2.2-13).\u001b[0m\u001b[3;34m                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m3. In adults with a family history of premature ASCVD or genetic hyperlipidemia, a fasting lipid profile is \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreasonable for initial evaluation to aid in the understanding and identification of familial lipid disorders \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S2.2-12, S2.2-13).\u001b[0m\u001b[3;34m                                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2.3. Measurements of Apolipoprotein B and Lipoprotein (a)\u001b[0m\u001b[3;34m                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTwo lipoprotein entities related to LDL-C are apoB and lipoprotein (a) [Lp(a)]. Because apoB is the major \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mapolipoprotein embedded in LDL and VLDL, several investigators identify strength of association between apoB \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand ASCVD (S2.3-1). Others report a high correlation between apoB and non–HDL-C (S2.3-2). Under certain \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcircumstances, particularly in patients with hypertriglyceridemia, the measurement of apoB may have advantages \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S2.3-3). Nevertheless, apoB measurement carries extra expense, and its measurement in some laboratories may \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mnot be reliable (S2.3-4). A relative indication for its measurement would be triglyceride $200 mg/dL. A level \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m>130 mg/dL corresponds to an LDL-C level $160 mg/dL and constitutes a risk-enhancing factor. A persistent \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34melevation of apoB can be considered a risk-enhancing factor. Separately, Lp(a) is a modified form of LDL that \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mappears to possess atherogenic potential (S2.3-5). Relative indications for its measurement are family history \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof premature ASCVD or personal history of ASCVD not explained by major risk factors. Lp(a) increases ASCVD risk\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mespecially at higher levels. Thus, if a decision is made to measure Lp(a), an Lp(a) $50 mg/dL or $125 nmol/L, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLp(a) may be considered a risk-enhancing factor (S2.3-6). Current evidence shows that it should be considered \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34min women only in the presence of hypercholesterolemia and with the understanding that the improvement in risk \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mprediction in adult women in a large clinical trial was minimal (S2.3-7). In the present document, an elevation\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof Lp(a) is considered to be a risk-enhancing factor (S2.3-6). This is especially in those with higher Lp(a) \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mvalues and, if used in women, only in the presence of hypercholesterolemia (S2.3-7).\u001b[0m\u001b[3;34m                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2.4. Monitoring Response of LDL-C to Statin Therapy\u001b[0m\u001b[3;34m                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mIn large RCTs of cholesterol-lowering therapy, LDL-C lowering has been consistently shown to reduce the risk of\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mASCVD. One large meta-analysis (S2.4-1) of statin clinical trials showed a progressive reduction in risk of \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmajor ASCVD events with lower on-treatment LDL-C levels. In another larger meta-analysis (S2.4-2) of 14 statin \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtrials, it was observed that a 38.7-mg/dL (1-mmol/L) reduction of LDL-C levels is accompanied by a 21% \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduction in ASCVD risk. In clinical practice, however, absolute responses in LDL-C to statin therapy depend on\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbaseline\u001b[0m\u001b[3;34m                                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: search_bing                                                                        │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: search_bing\u001b[0m\u001b[1;35m                                                                       \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\": \"FDA medication updates hyperlipidemia February 2025\"}                 │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\": \"FDA medication updates hyperlipidemia February 2025\"}\u001b[0m\u001b[35m                \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': 'FDA medication updates hyperlipidemia February 2025'}   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': 'FDA medication updates hyperlipidemia February 2025'}\u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_bing                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"FDA medication updates hyperlipidemia February 2025\"                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_bing\u001b[0m\u001b[1;34m                                                                         \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"FDA medication updates hyperlipidemia February 2025\"\u001b[0m\u001b[1;34m                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: search_bing with args: {'query': 'FDA medication updates           │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ hyperlipidemia February 2025'}                                                                                  │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: search_bing with args: {'query': 'FDA medication updates \u001b[0m\u001b[1;35m         \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mhyperlipidemia February 2025'}\u001b[0m\u001b[1;35m                                                                                 \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ Tool Invoked: Bing Search                                                                                       │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ Query: FDA medication updates hyperlipidemia February 2025                                                      │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mTool Invoked: Bing Search\u001b[0m\u001b[1;35m                                                                                      \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mQuery: FDA medication updates hyperlipidemia February 2025\u001b[0m\u001b[1;35m                                                     \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output: The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Application (BLA) and making a final decision on marketing approval. The typical period for review is 10 months │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ after the drug application has been accepted by the Agency.                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ CINCINNATI- February 10, 2025 --LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ License Application (BLA) of Lerodalcibep to reduce low-density lipoprotein cholesterol (LDL-C) for the         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ treatment of patients with atherosclerotic cardiovascular disease (ASCVD), or ...                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The FDA has accepted for review the biologics license application (BLA) of lerodalcibep (LIB Therapeutics) to │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduce low-density lipoprotein cholesterol (LDL-C) in the treatment of patients with atherosclerotic            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ cardiovascular disease (ASCVD), or very high or high risk of ASCVD, and primary hyperlipidemia, including     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ heterozygous patients and those 10 years or older with homozygous familial ...                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Topic Guidance Status Date; Clinical - Medical: Obesity and Overweight: Developing Drugs and Biological       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Products for Weight Reduction: Draft: 1/7/2025: Clinical/Medical                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The US Food and Drug Administration (FDA) granted an updated indication for bempedoic acid (Nexletol,       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Esperion Therapeutics Inc) and bempedoic acid plus ezetimibe (Nexlizet, Esperion Therapeutics Inc) for the      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ treatment of primary hyperlipidemia in eligible patients with genetic hyperlipidemia or atherosclerotic     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ cardiovascular disease, according to an Esperion press release.                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The FDA approved an updated indication for Esperion’s bempedoic acid tablet (Nexletol) and bempedoic acid and │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ezetimibe tablet (Nexlizet) to include treatment of primary hyperlipidemia as a qualifier for existing        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ approved populations, the pharmaceutical company announced in a press release. 1 In addition to the updated     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ indication, the federal agency also removed the maximally tolerated ...                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ In June 2023, Leqembi (lecanemab) became the first fully FDA-approved medication of its kind of Alzheimer’s │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ disease. It’s thought to work by targeting beta-amyloid plaques to slow the progression of the disease. Fast    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ forward to January 2025, and the FDA approved a once-monthly maintenance dosage of Leqembi. This gave       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ people receiving ...                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Bempedoic acid was first approved in 2020 to lower LDL cholesterol in adults with heterozygous familial         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypercholesterolemia or established atherosclerotic cardiovascular disease. 2 Then in December 2023, the FDA  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ approved a label expansion for bempedoic acid tablet and bempedoic acid and ezetimibe tablet to include         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ treatment of primary hyperlipidemia as a qualifier for existing approved ...                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ On 21 February 2025, the FDA announced that the US semaglutide injection product shortage has resolved,   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ such that semaglutide can now be removed from the drug shortages list.The FDA has confirmed ...             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ To help stakeholders better understand the guidance, the FDA will host a webinar on March 4, 2025. • Read   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ the final guidance here. Conclusion. The breadth of these updates reflects the FDA’s ongoing efforts to     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ enhance regulatory clarity and ensure public health safety across various sectors.                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output: The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthe US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mApplication (BLA) and making a final decision on marketing approval. The typical period for review is 10 months\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mafter the drug application has been accepted by the Agency.\u001b[0m\u001b[3;34m                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCINCINNATI- February 10, 2025 --LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcompany today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLicense Application (BLA) of Lerodalcibep to reduce low-density lipoprotein cholesterol (LDL-C) for the \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtreatment of patients with atherosclerotic cardiovascular disease (ASCVD), or ...\u001b[0m\u001b[3;34m                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe FDA has accepted for review the biologics license application (BLA) of lerodalcibep (LIB Therapeutics) to\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduce low-density lipoprotein cholesterol (LDL-C) in the treatment of patients with atherosclerotic \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcardiovascular disease (ASCVD), or very high or high risk of ASCVD, and primary hyperlipidemia, including \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mheterozygous patients and those 10 years or older with homozygous familial ...\u001b[0m\u001b[3;34m                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTopic Guidance Status Date; Clinical - Medical: Obesity and Overweight: Developing Drugs and Biological \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mProducts for Weight Reduction: Draft: 1/7/2025: Clinical/Medical\u001b[0m\u001b[3;34m                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe US Food and Drug Administration (FDA) granted an updated indication for bempedoic acid (Nexletol, \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mEsperion Therapeutics Inc) and bempedoic acid plus ezetimibe (Nexlizet, Esperion Therapeutics Inc) for the \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtreatment of primary hyperlipidemia in eligible patients with genetic hyperlipidemia or atherosclerotic \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcardiovascular disease, according to an Esperion press release.\u001b[0m\u001b[3;34m                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe FDA approved an updated indication for Esperion’s bempedoic acid tablet (Nexletol) and bempedoic acid and\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mezetimibe tablet (Nexlizet) to include treatment of primary hyperlipidemia as a qualifier for existing \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mapproved populations, the pharmaceutical company announced in a press release. 1 In addition to the updated \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mindication, the federal agency also removed the maximally tolerated ...\u001b[0m\u001b[3;34m                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mIn June 2023, Leqembi (lecanemab) became the first fully FDA-approved medication of its kind of Alzheimer’s\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdisease. It’s thought to work by targeting beta-amyloid plaques to slow the progression of the disease. Fast \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mforward to January 2025, and the FDA approved a once-monthly maintenance dosage of Leqembi. This gave \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpeople receiving ...\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mBempedoic acid was first approved in 2020 to lower LDL cholesterol in adults with heterozygous familial \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypercholesterolemia or established atherosclerotic cardiovascular disease. 2 Then in December 2023, the FDA \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mapproved a label expansion for bempedoic acid tablet and bempedoic acid and ezetimibe tablet to include \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtreatment of primary hyperlipidemia as a qualifier for existing approved ...\u001b[0m\u001b[3;34m                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mOn 21 February 2025, the FDA announced that the US semaglutide injection product shortage has resolved, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msuch that semaglutide can now be removed from the drug shortages list.The FDA has confirmed ...\u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTo help stakeholders better understand the guidance, the FDA will host a webinar on March 4, 2025. • Read \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthe final guidance here. Conclusion. The breadth of these updates reflects the FDA’s ongoing efforts to \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34menhance regulatory clarity and ensure public health safety across various sectors.\u001b[0m\u001b[3;34m                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='### Summary for Patient Gloria             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Paul\\n\\n#### Patient Medical Details:\\n- **Name:** Gloria Paul\\n- **Date of Birth:** July 15, 1944 (79 years    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ old)\\n- **Gender:** Other\\n- **Location:** Lewisberg, MN, India\\n- **Medical Condition:** Hyperlipidemia\\n-     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ **Medications:** Atorvastatin\\n- **Allergies:** None\\n- **Blood Type:** O+\\n- **Last Visit Date:** March 26,    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2024\\n- **Lifestyle Factors:**\\n  - **Smoking Status:** Never smoker\\n  - **Alcohol Consumption:** Light        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ drinker (1-2 times a week)\\n  - **Exercise Frequency:** Regular exercise\\n\\n#### ACC Guidelines for             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Hyperlipidemia:\\n1. **Class I Recommendations:**\\n   - Statin treatment is recommended for all patients with    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ atherosclerosis (including carotid or vertebral atherosclerosis), aiming to reduce LDL cholesterol below 100    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mg/dL.\\n   \\n2. **Class IIa Recommendations:**\\n   - Statins may also be considered for ischemic stroke         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients to achieve LDL levels around or below 70 mg/dL.\\n   - For patients not achieving desired LDL levels    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with statins, additional medications such as bile acid sequestrants or niacin may be beneficial.\\n   -          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Alternatives to statins, like bile acid sequestrants, are reasonable for those intolerant to statins.\\n\\n3.     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ **Lifestyle Modifications:** Address lifestyle factors, including obesity or metabolic syndrome, alongside any  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ underlying secondary conditions.\\n\\n#### FDA Updates (as of February 2025):\\n- **Lerodalcibep**: A new          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ biologics license application has been submitted to the FDA targeting low-density lipoprotein cholesterol       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (LDL-C) for the treatment of patients with atherosclerotic cardiovascular disease or those with primary         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia.\\n  \\n- **Bempedoic Acid Update**: The FDA has updated the indication for bempedoic acid         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (Nexletol) to treat primary hyperlipidemia among eligible patients with genetic hyperlipidemia or               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ atherosclerotic cardiovascular disease.\\n\\n### Conclusion:\\nFor Mrs. Gloria Paul, FDA updates indicate the      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ potential introduction of new medications for managing hyperlipidemia that could complement or enhance her      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ current treatment with atorvastatin. Based on the ACC guidelines, continuing atorvastatin is appropriate, with  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ a focus on achieving optimal LDL cholesterol levels. Regular check-ups and monitoring of her lipid profile      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ would be essential for optimizing her treatment plan.', refusal=None, role='assistant', audio=None,             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function_call=None, tool_calls=None)                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='### Summary for Patient Gloria \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mPaul\\n\\n#### Patient Medical Details:\\n- **Name:** Gloria Paul\\n- **Date of Birth:** July 15, 1944 (79 years \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mold)\\n- **Gender:** Other\\n- **Location:** Lewisberg, MN, India\\n- **Medical Condition:** Hyperlipidemia\\n- \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m**Medications:** Atorvastatin\\n- **Allergies:** None\\n- **Blood Type:** O+\\n- **Last Visit Date:** March 26, \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2024\\n- **Lifestyle Factors:**\\n  - **Smoking Status:** Never smoker\\n  - **Alcohol Consumption:** Light \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdrinker (1-2 times a week)\\n  - **Exercise Frequency:** Regular exercise\\n\\n#### ACC Guidelines for \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHyperlipidemia:\\n1. **Class I Recommendations:**\\n   - Statin treatment is recommended for all patients with \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2matherosclerosis (including carotid or vertebral atherosclerosis), aiming to reduce LDL cholesterol below 100 \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmg/dL.\\n   \\n2. **Class IIa Recommendations:**\\n   - Statins may also be considered for ischemic stroke \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients to achieve LDL levels around or below 70 mg/dL.\\n   - For patients not achieving desired LDL levels \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith statins, additional medications such as bile acid sequestrants or niacin may be beneficial.\\n   - \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mAlternatives to statins, like bile acid sequestrants, are reasonable for those intolerant to statins.\\n\\n3. \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m**Lifestyle Modifications:** Address lifestyle factors, including obesity or metabolic syndrome, alongside any \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2munderlying secondary conditions.\\n\\n#### FDA Updates (as of February 2025):\\n- **Lerodalcibep**: A new \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbiologics license application has been submitted to the FDA targeting low-density lipoprotein cholesterol \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(LDL-C) for the treatment of patients with atherosclerotic cardiovascular disease or those with primary \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia.\\n  \\n- **Bempedoic Acid Update**: The FDA has updated the indication for bempedoic acid \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(Nexletol) to treat primary hyperlipidemia among eligible patients with genetic hyperlipidemia or \u001b[0m\u001b[2m             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2matherosclerotic cardiovascular disease.\\n\\n### Conclusion:\\nFor Mrs. Gloria Paul, FDA updates indicate the \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpotential introduction of new medications for managing hyperlipidemia that could complement or enhance her \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcurrent treatment with atorvastatin. Based on the ACC guidelines, continuing atorvastatin is appropriate, with \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2ma focus on achieving optimal LDL cholesterol levels. Regular check-ups and monitoring of her lipid profile \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwould be essential for optimizing her treatment plan.', refusal=None, role='assistant', audio=None, \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction_call=None, tool_calls=None)\u001b[0m\u001b[2m                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### Summary for Patient Gloria Paul                                                                             </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> #### Patient Medical Details:                                                                                   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Name:** Gloria Paul                                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Date of Birth:** July 15, 1944 (79 years old)                                                               </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Gender:** Other                                                                                             </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Location:** Lewisberg, MN, India                                                                            </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Medical Condition:** Hyperlipidemia                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Medications:** Atorvastatin                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Allergies:** None                                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Blood Type:** O+                                                                                            </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Last Visit Date:** March 26, 2024                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Lifestyle Factors:**                                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">   - **Smoking Status:** Never smoker                                                                            </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">   - **Alcohol Consumption:** Light drinker (1-2 times a week)                                                   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">   - **Exercise Frequency:** Regular exercise                                                                    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> #### ACC Guidelines for Hyperlipidemia:                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 1. **Class I Recommendations:**                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - Statin treatment is recommended for all patients with atherosclerosis (including carotid or vertebral      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> atherosclerosis), aiming to reduce LDL cholesterol below 100 mg/dL.                                             </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 2. **Class IIa Recommendations:**                                                                               </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - Statins may also be considered for ischemic stroke patients to achieve LDL levels around or below 70       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> mg/dL.                                                                                                          </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - For patients not achieving desired LDL levels with statins, additional medications such as bile acid       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> sequestrants or niacin may be beneficial.                                                                       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - Alternatives to statins, like bile acid sequestrants, are reasonable for those intolerant to statins.      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 3. **Lifestyle Modifications:** Address lifestyle factors, including obesity or metabolic syndrome, alongside   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> any underlying secondary conditions.                                                                            </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> #### FDA Updates (as of February 2025):                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Lerodalcibep**: A new biologics license application has been submitted to the FDA targeting low-density     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> lipoprotein cholesterol (LDL-C) for the treatment of patients with atherosclerotic cardiovascular disease or    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> those with primary hyperlipidemia.                                                                              </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Bempedoic Acid Update**: The FDA has updated the indication for bempedoic acid (Nexletol) to treat primary  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> hyperlipidemia among eligible patients with genetic hyperlipidemia or atherosclerotic cardiovascular disease.   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### Conclusion:                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> For Mrs. Gloria Paul, FDA updates indicate the potential introduction of new medications for managing           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> hyperlipidemia that could complement or enhance her current treatment with atorvastatin. Based on the ACC       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> guidelines, continuing atorvastatin is appropriate, with a focus on achieving optimal LDL cholesterol levels.   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> Regular check-ups and monitoring of her lipid profile would be essential for optimizing her treatment plan.     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### Summary for Patient Gloria Paul\u001b[0m\u001b[1;32m                                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m#### Patient Medical Details:\u001b[0m\u001b[1;32m                                                                                  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Name:** Gloria Paul\u001b[0m\u001b[1;32m                                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Date of Birth:** July 15, 1944 (79 years old)\u001b[0m\u001b[1;32m                                                              \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Gender:** Other\u001b[0m\u001b[1;32m                                                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Location:** Lewisberg, MN, India\u001b[0m\u001b[1;32m                                                                           \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Medical Condition:** Hyperlipidemia\u001b[0m\u001b[1;32m                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Medications:** Atorvastatin\u001b[0m\u001b[1;32m                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Allergies:** None\u001b[0m\u001b[1;32m                                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Blood Type:** O+\u001b[0m\u001b[1;32m                                                                                           \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Last Visit Date:** March 26, 2024\u001b[0m\u001b[1;32m                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Lifestyle Factors:**\u001b[0m\u001b[1;32m                                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m  - **Smoking Status:** Never smoker\u001b[0m\u001b[1;32m                                                                           \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m  - **Alcohol Consumption:** Light drinker (1-2 times a week)\u001b[0m\u001b[1;32m                                                  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m  - **Exercise Frequency:** Regular exercise\u001b[0m\u001b[1;32m                                                                   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m#### ACC Guidelines for Hyperlipidemia:\u001b[0m\u001b[1;32m                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m1. **Class I Recommendations:**\u001b[0m\u001b[1;32m                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - Statin treatment is recommended for all patients with atherosclerosis (including carotid or vertebral \u001b[0m\u001b[1;32m    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32matherosclerosis), aiming to reduce LDL cholesterol below 100 mg/dL.\u001b[0m\u001b[1;32m                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   \u001b[0m\u001b[1;32m                                                                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m2. **Class IIa Recommendations:**\u001b[0m\u001b[1;32m                                                                              \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - Statins may also be considered for ischemic stroke patients to achieve LDL levels around or below 70 \u001b[0m\u001b[1;32m     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mmg/dL.\u001b[0m\u001b[1;32m                                                                                                         \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - For patients not achieving desired LDL levels with statins, additional medications such as bile acid \u001b[0m\u001b[1;32m     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32msequestrants or niacin may be beneficial.\u001b[0m\u001b[1;32m                                                                      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - Alternatives to statins, like bile acid sequestrants, are reasonable for those intolerant to statins.\u001b[0m\u001b[1;32m     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m3. **Lifestyle Modifications:** Address lifestyle factors, including obesity or metabolic syndrome, alongside \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32many underlying secondary conditions.\u001b[0m\u001b[1;32m                                                                           \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m#### FDA Updates (as of February 2025):\u001b[0m\u001b[1;32m                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Lerodalcibep**: A new biologics license application has been submitted to the FDA targeting low-density \u001b[0m\u001b[1;32m   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mlipoprotein cholesterol (LDL-C) for the treatment of patients with atherosclerotic cardiovascular disease or \u001b[0m\u001b[1;32m  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mthose with primary hyperlipidemia.\u001b[0m\u001b[1;32m                                                                             \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m  \u001b[0m\u001b[1;32m                                                                                                             \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Bempedoic Acid Update**: The FDA has updated the indication for bempedoic acid (Nexletol) to treat primary \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mhyperlipidemia among eligible patients with genetic hyperlipidemia or atherosclerotic cardiovascular disease.\u001b[0m\u001b[1;32m  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### Conclusion:\u001b[0m\u001b[1;32m                                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mFor Mrs. Gloria Paul, FDA updates indicate the potential introduction of new medications for managing \u001b[0m\u001b[1;32m         \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mhyperlipidemia that could complement or enhance her current treatment with atorvastatin. Based on the ACC \u001b[0m\u001b[1;32m     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mguidelines, continuing atorvastatin is appropriate, with a focus on achieving optimal LDL cholesterol levels. \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mRegular check-ups and monitoring of her lipid profile would be essential for optimizing her treatment plan.\u001b[0m\u001b[1;32m    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "run_multi_step_agent(\"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can you confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if there are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
